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Angiotensin-converting enzyme (ACE) is a zinc metallopeptidase and a key drug target for 
the treatment of hypertension, due to its action on vasoregulatory peptides angiotensin I and 
bradykinin. ACE consists of two active domains, the N and C domains, having similar 
structures and activities. Each domain is globular and largely a-helical, with the active zinc 
ion buried in a cleft that divides the domain in half. Some substrates are cleaved 
preferentially by one domain, with the cleavage of angiotensin I depending largely on the C 
domain. It has been suggested that C-domain-selective inhibitors might not cause the side 
effects arising from current ACE inhibitor therapies. Here, X-ray co-crystal structures have 
been solved of three novel C-domain-selective inhibitors in the active site of a glycosylation-
deficient mutant of human testis ACE, tACE-G 13, equivalent to the minimally-glycosylated C 
domain. This is the first successful application of this mutant in the drug design process. 
Inhibitors (5S)-5-[(N-benzoyl)amino]-4-oxo-6-phenyl-hexanoyl-L-tryptophan (kA W) and 
(5S)-5-[(N -benzoyl)amino ]-4-oxo-6-phenyl-hexanoyl-L-phenylalanine (kAF) were derived 
from keto-ACE by P2' substitution. Their co-crystal structures, to 2.18 and 2.17 A, 
respectively, reveal the hydrated geminal diolate form of the ketone zinc-binding group, 
reminiscent of the tetrahedral transition state. Two enantiomers of inhibitor (SR)-I-(N(2)-(1-
carboxy-3-phenylpropyl)-L-Iysyl)-L-tryptophan (lisW) were derived from lisinopril by P2' 
substitution, however structures solved to 2.40 and 2.30 A revealed the selection of the L-
amino-acid form, lisW-S, by the active site. Inter-domain substitutions have been identified 
among the side chains interacting with these three inhibitors which account for their domain-
selectivity. Based on this work, several of these substitutions, E376D, V380T, Y391F and 
V518S, have subsequently been verified as important for the domain-selectivity ofkA Wand 
kAF. The P2' Trp moieties ofkA Wand lisW-S take different conformations in the active site, 
indicating the large volume of the S2' pocket and cooperativity of binding between the P2' and 
PI'moieties. Conserved active site water molecules were identified, including water 1165 of 
the kA W structure which may be important for the chloride activation of the C domain due to 
its proximity to the chloride ligand R522. These data provide a platform for further structure-
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CHAPTER 1: Introduction 2 
1.1. Hypertension and the discovery of angiotensin-converting enzyme 
1.1.1. The discovery of angiotensin-converting enzyme 
Arterial hypertension is a medical condition characterised by elevated blood pressure, which 
frequently contributes to the development of cardiac disease and chronic renal failure. Its 
causes and treatment have been the subjects of speculation and serious scientific investigation 
since as early as 2600 BC (reviewed briefly by Esunge (1991)). In the 1950's it became 
apparent that a substance found in the blood plasma of hypertensive humans and animals 
induced an increase in blood pressure when administered to test animals. The substance, then 
named hypertensin, was produced by the enzyme renin and was found to exist in inactive 
(hypertensin I) and active (hypertensin II) forms (Skeggs et al., 1954). Since injection of 
either form into test animals resulted in an increase in blood pressure, a "hypertensin-
converting enzyme" which catalysed the rapid conversion of hypertensin I to hypertensin II, 
was hypothesised and then isolated (Skeggs et al., 1956). This enzyme, now known variously 
as angiotensin-converting enzyme (ACE; EC 3.4.15.1), peptidyl-dipetidase A or dipeptidyl 
carboxypeptidase I, was found to be a zinc-metallopeptidase expressed in most mammalian 
tissues, and a key component of what came to be known as the renin-angiotensin system 
(RAS). 
1.1.2. The renin-angiotensin and kallikrein-kinin systems 
In the circulating RAS (reviewed by Erdos (1990) and Zaman et al. (2002)), angiotensin I 
(AI, previously hypertensin I), a decapeptide, is derived from the action of the aspartic 
protease renin on angiotensinogen, a 118 amino-acid protein precursor synthesised in the 
liver. AI is in turn cleaved by ACE to produce the vasopressor octapeptide angiotensin II 
(AU, previously hypertensin II). The effects of AIl are mediated by two G-protein-coupled 
receptors. Receptor ATl mediates the classic vasoconstrictor effects, while receptor AT2 is 
expressed abundantly during foetal development and at sites of cellular stress in adults, where 
it mediates vasodilation, cell differentiation and tissue repair among other effects. 
In addition to its RAS function, ACE was also found to be the same enzyme as "kininase II" 
of the kallikrein-kinin system (KKS, reviewed by Skidgel & Erdos (2004) and Moreau et al. 
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kininogens by a number of different proteases, binds to the B2 kinin receptor, causing 
vasodilation and increased vascular permeability. The action of ACE on BK produces an 
inactive heptapeptide which is unable to bind to the B2 receptor. ACE thus acts on two 
vasoregulatory peptides, causing an increase in blood pressure in both cases. 
Based on this understanding of its dual hypertension-inducing activities in the RAS and KKS, 
ACE was identified as an inhibitor target. The history of ACE drug design has been reviewed 
by de Lima (1999) and Acharya et al. (2003). Today ACE inhibitors are commonly used in 
the treatment of hypertension, congestive heart failure, myocardial infarction and diabetic 
nephropathy (Table 1.1; Sica, 2004). 
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1.2. ACE primary structure 
1.2.1. The ACE gene encodes two homologous domains 
When the ACE gene was sequenced in 1988, it was found to consist of two homologous 
domains (the N-tenninal or N domain and CMtenninal or C domain), each containing a zinc-
binding motif of the sequence HEMGH + E (Soubrier et al., 1988). This motif places ACE in 
the M2 family of the MA (zinc ins ) clan of zinc metallopeptidases, which are characterised by 
the zinc binding motif HEXXH + E, containing two zinc-binding histidines, with a 
downstream glutamate as the third zinc ligand (reviewed by Turner & Hooper (2002) and 
Spyroulias et al. (2004)). 
The Nand C domains are approximately 55% identical to one another and both are active on 
peptide substrates (Wei et al., 1991). They are preceded by a signal peptide (29 residues) 
targeting expression to the cell membrane, separated by a flexible linker peptide (about 11 
residues) and have an additional 78 C-tenninal residues comprising stalk, juxtamembrane, 
transmembrane and cytoplasmic tail regions (Appendix A; Hubert et al., 1991). A second 
promoter in intron 12 of the ACE gene contains a cyclic AMP responsive element which 
results in the tissue-specific expression of a single domain isofonn, testis ACE (tACE), in 
developing spenn cells (Hubert et al., 1991; Langford et al., 1993; Esther, Jr. et al., 1997). 
tACE is identical to the C domain of ACE, except for an additional 56-residue N-tenninal 
signal peptide and O-glycosylated region (Ehlers et al., 1989). 
The N-terminal signal peptide is cleaved off during post-translational processing, and both 
isofonns are shed from the cell membrane by the action of a putative ACE sheddase at a site 
in the stalk region (Ehlers et al., 1996). This shedding, together with the evidence for high 
levels of ACE expression in lung endothelia (Ehlers & Riordan, 1989), explains how soluble 
ACE comes to fonn part of the circulating RAS and KKS. 
1.2.2. Polymorphisms in the ACE gene 
Since 1988, the human ACE gene has been studied in some detail, and a number of 
polymorphisms have been identified. Most significant among these is a common noncoding 
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1990). Individuals with the DID genotype have increased blood and tissue ACE activity 
relative to those having the VI phenotype, and as could be expected this polymorphism has 
been implicated in susceptibility to a number of ACE-related disease states (reviewed by 
Sayed-Tabatabaei et ai. (2006)). In addition to this polymorphism, 73 single nucleotide 
polymorphisms (SNPs) are listed by the SNP database (dbSNP) at NCBI (the National Centre 
for Biotechnology Information, http://www.ncbi.nlm.nih.govl) as falling in the ACE gene 
locus. Thirty-one of these fall within coding regions of the gene, however only one coding 
SNP is associated with a known phenotype: a point mutation that results in the coding 
mutation P1199L near the sheddase site in the stalk region results in an increase in shedding 
and a non-pathogenic increase in serum ACE levels (Kramers et ai., 2001). 
1.3. ACE in other species 
The sequence of ACE is highly conserved (> 80% identical) among mammals, and rodent, 
porcine, rabbit and bovine ACE have been studied as models for human ACE activity. Such 
studies were initially carried out in vitro when the tissues of these animals were used as 
sources of purified ACE (for example Bunning et al. (1983) and Voronov et ai. (2002)). 
More recently in vivo studies have been undertaken (for example Binevski et al. (2003), 
Georgiadis et al. (2003) and Ocaranza et al. (2006)), however it should be noted that the 
alterations in sequence between species have been shown to correlate with small changes in 
ACE substrate specificity and chloride dependence, so that conclusions drawn from studies 
with other mammalian ACEs should be extrapolated to human ACE only with caution 
(Ibarrarubio et al., 1993; Jullien et al., 2006). 
ACE-related sequences also occur in a wide variety of organisms across the phylogenetic 
spectrum, and active ACE homologues have been identified in several non-mammalian 
species, including a number of insect species and annelids (Williams et ai., 1996; Macours et 
ai.,2004). Remarkably, an ACE homologue from the bacterium Xanthomonas axonopodis 
was recently found to be active, and to have a similar substrate and inhibitor profile to 
mammalian ACE (Riviere et ai., 2007). This ubiquity across phyla suggests a conserved 
fundamental role for ACE, which is supported by the observation that insect ACE plays a 
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1.4. ACE substrates and inhibitors - domain-selectivity 
1.4.1. Two domains result in dual activity 
The presence of two active domains in ACE does not simply amount to a duplication of 
activity, but rather a dual activity, since the 45% of residues which are non-identical confer a 
certain degree of dissimilarity in kinetic properties between the N and C domains. For 
instance, the N domain is more thermally stable than the C domain (Voronov et ai., 2002) and 
less strongly activated by chloride ions (Wei et ai., 1991). Most notable in the context of 
inhibitor design, however, are differences in substrate and inhibitor specificity. 
ACE can act on a range of peptide substrates. Its primary activity is as a C-terminal 
dipeptidase, but it is also capable of endopeptidase and tripeptidase activity on substrates with 
amidated C-termini (Ehlers & Riordan, 1991; Skidgel & Erdos, 2004; Naqvi et ai., 2005). 
Substrate binding is described using a subsite model, with Sl, S2, S3, S4, etc. describing 
substrate side chain binding pockets increasingly distant from the scissile peptide bond to the 
N-terminal side, and SI', S2' (and occasionally S3') describing binding pockets for side chains 
increasingly distant on the C-terminal side. The equivalent side chains in the peptide 
substrate are referred to as PI, P2, P3, P4 or PI', P2', P3'. 
1.4.2. Domain-selectivity ofk:nown substrates and inhibitors 
The vasoregulatory peptides AI and BK have approximately equal affinity for both ACE 
domains, however AI cleavage is carried out more efficiently by the C domain than the N 
domain in vitro (Wei et al., 1991). In addition to AI and BK, ACE cleaves a number of 
physiological peptides in vitro, including RAS and KKS peptides, neuropeptides, hormones 
and growth factors (see Table 1.2), and is also thought to be involved in the removal of basic 
C-terminal residues during prohormone processing (Isaac et ai., 1999). These additional 
activities illustrate the broad sequence specificity of ACE as well as implicating the enzyme 
in a more complex functionality than simply the regulation of blood pressure. Among these 
additional substrates, p-neoendorphin, AcSDKP, Angl-7, GnRH and amyloid P peptide are 
preferentially cleaved by the N domain (Jaspard et ai., 1993; Deddish et al., 1998; Junot et ai., 
2001; Oba et al., 2005), with Ang l -7 actually having an inhibitory effect on the C domain 
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A degree of domain-selectivity is also observed with several of the ACE inhibitors currently 
in clinical use (Table 1.3), despite the fact that these inhibitors were designed without 
knowledge of the two-domain structure of ACE. For example, the tripeptide analogue 
lisinopril has as much as I8-fold higher affinity for the C domain than for the N domain 
(Table 1.3; Wei et aI., 1992). Moreover, the short peptide substrate commonly used to assay 
for ACE activity, Hippuryl-His-Leu (Friedland & Silverstein, 1976), is cleaved approximately 
lO-fold more efficiently by the C domain than by the N domain (Jaspard et al., 1993). 
Bradykinin-potentiating peptides (BPPs) are naturally-occurring ACE inhibitors found in 
snake venom, which were instrumental in the development of captopril, the first ACE 
inhibitor to be used as an antihypertensive treatment (Ondetti et al., 1977; de Lima, 1999; 
Hayashi & Camargo, 2005). They constitute a natural set of peptide inhibitors of varying 
sequence, many of which display strong domain-selectivity (Table 1.4; Cotton et al., 2002; 
Hayashi & Camargo, 2005). Another inhibitor based on the BPP sequences and also designed 
early in the search for antihypertensive treatments, is keto-ACE, an analogue ofbenzoyl-FGP 
with a keto methylene group replacing the scissile bond (Almquist et al., 1980). This inhibitor 
was also found to be moderately selective for the C domain (Deddish et al., 1998). 
Examination of these compounds, together with studies using synthetic peptide libraries (for 
example, Michaud et al., 1999; Cotton et al., 2002; Bersanetti et al., 2004; Jullien et aI., 
2006), has yielded some insight into the determinants of domain-selectivity. C-domain-
selectivity has been suggested to be caused by among other things, bulky Ph Pi' or P2' groups 
(Perich et al., 1994; Acharya et al., 2003), or a P2 Lys (Cotton et aI., 2002). However, these 
determinants are complicated by cooperativity between side chains which can affect domain 
affinity (Michaud et al., 1999). 
University of Cape Town
Table 1.2. Sequence and functional diversity of biological peptide substrates of ACE. 
Substrate 
Vasoregulatory pep tides 






Other biological peptides 
Sequence and cleavage site(s)' Notes on cleavage and fUllction. 
H,N-DRVYlliPF II-fL-COOH First physiological substrate discovered. Cleaved by both domains (Jaspard el al., 1993). 
HlN-RPPGFSP / FR-COOl l Second physiological substrate discovered. Cleaved by both domains (Jaspard el al., \993). 
I-IlN-DRVYI/ HP / FH-COOI I Inactive product of AI cleavage by human ACE homologue ACE2 (Eriksson el al., 2002). 
H1N-DRVYI / HP-COOII Product of the action ofneuual endopeptidase on AI or of ACE2 on All. Binds Angl.7 receptor, with similar 
functions to those of AI via the AT2 receptor (reviewed by Acharya el al. (2003)). Cleaved by the N domain, 
inhibits the C domain (Deddish el al., 1998). 
H1N-RPPGF / SPF-COO) I C-terminal tripeptidase activity (lnokuchi & Nagamatsu, 1981). 
H,N-RPPG / F / SP-COOH Produced from BK by action of ACE in vitro; C-terminal di- or tripeptidase activity. (Inokuchi & Nagamatsu, 
1981; Jaspard el al., 1993). 
Amyloid ~ peptide H,N-DAEFRHD / 
SGYEVHHQKL VFF AEDVGSNKGAlIGLMVGGVVIA-COOH 
Fomls plaques in Alzheimer's disease. Cleavage by ACE is thought to reduce plaque fonnation (Hemming & 
Selkoe,2005). Preferentially cleaved by the N domain acting as an endopeptidase (Oba el aI., 2005). 






pEHW / SYG / LRP-CONH, 
H3N-RP / KPGGFF / G / LM-CONH, 
H3N-YGGFL / RK / YP-COOII 
H3N-YGG / FM-COOH 
H3N-ELYENKPRRPY / IL-CON I h 
FMel-LF-COOll 
Reproductive hormone with a modified N- and C-termini. Tripeptidase activity on either end; cleaved 
preferentially by the N domain (Skidgel & Erdos, 1985; Jaspard et al., 1993). 
Neuropeptide cleaved in two orientations, with tripeptidase or dipeptidase activity (reviewed by Zaman el al. 
(2002), Naqvi el al. (2005) and Jaspard et al. (I993)). 
Neuropeptide and endogenous opioid, cleaved sequentially by ACE to yield Leu-enkephalin (~-neoendorphinl_ 
7) and ~-neoendorphinl_5 (Hayakari el al., 1997). 
Opioid neuropeptide. Reviewed by Erdos (1990). 
Neuropeptide (Skidgel et al., 1984). 
Chemotactic peptide. Reviewed by Erdos (1990). 
N-AcSDKP Ac-SD / KP-COOII Haematopoietic signalling peptide. Cleaved by the N domain (Georgiadis el al., 2003) 
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1.4.3. Domain-selective inhibitors and domain cooperativity 






In recent years, phosphinic peptide inhibitors RXP407 and RXP A380 have been identified as 
having strong selectivity for the N and C domains respectively, allowing for complete 
inhibition of one domain at a time (Dive et al., 1999; Junot et al., 2001; Georgiadis et aI., 
2003; Georgiadis et al., 2004). Studies with RXP407 and RXPA380 revealed that inhibition 
of either the N or C domain alone resulted in inhibition of AI hydrolysis in vivo, while BK 
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Table 1.4 Sequences and domain affmity of bradykinin-potentiating peptides (Hayashi & Camargo, 2005). 
Bradykinin-potentiating Sequence a KiN domain KiCdomain C-domain-selectivity 
peptide (oM) (nM) (KiN domainlKiC domain) 




BPP-9a (BPPa) pEWPRPQIPP 100 100.00 
BPP-IOa pESWPGPNIPP 130 33 3.94 
BPP-IOb pENWPRPQIPP 
BPP-lOc (BPP2) pENWPHPQIPP 200 0.5 400.00 
BPP-lla pEWPRPTPQIPP 
BPP-llb pEGRAPGPPIPP 3000 57 52.63 
BPP-llc pEGRAPHPPIPP 2000 40 50.00 
BPP-lld pEGRPPGPPIPP 
BPP-lle pEARPPHPPIPP 100 300 0.33 
BPPb pEGLPPRPKIPP 10000 30 333.33 
BPPc pEGLPPGPPIPP 80 80 
BPP-12a pEGW A WPRPQIPP 
BPP-12b pEWGRPPGPPIPP 5 150 0.033 
BPP-12c pEWAQWPRPQIPP 
BPP-13a pEGGWPRPGPEIPP 50 50 
BPP-13b pEGGLPRPGPEIPP 
BPP-14a pEW AQWPRPTPQIPP 
• pE = pyroglutamic acid 
This finding suggests a degree of negative cooperativity between domains, which is supported 
by the active site titration of one mole of lisinopril per mole of ACE from various mammalian 
sources in vitro (Ehlers & Riordan, 1991; Binevski et aI., 2003; Andujar-Sanchez et aI., 
2004). 
However, the issue of domain cooperativity is not clearly understood, since the existence and 
degree of cooperativity seems to depend on the substrate and assay conditions, and on 
whether the study is carried out in vivo or in vitro. For example, studies in which RXP407 
and RXPA380 have been used to inhibit one domain at a time demonstrated continued (non-
cooperative) activity of the respective uninhibited domain towards two fluorogenic substrates 
as wen as AI and BK in vitro, and negative domain cooperativity in the cleavage of AI but not 
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RXP407 had no effect on circulating AlI levels in mice (Junot et al., 2001), and RXPA380 
but not RXP407 inhibited a response to injected AI in porcine arteries (van Esch et aI., 2005), 
suggesting that the C domain may be largely responsible for conversion of AI to AlI in vivo. 
These findings were confirmed by studies using ACE domain-inactivated mice, which 
revealed that an active C domain is both necessary and sufficient in vivo to carry out normal 
AI processing in mice, whereas BK processing proceeds normally whichever domain is 
inactivated (Fuchs et ai., 2004; Fuchs et aI., 2007). 
1.5. The three-dimensional structure of ACE 
1.5.1. The problem of glycosylation and three-dimensional structure solution 
ACE is a glycoprotein with 16 potential N-linked glycosylation sites (Appendix A), nine in 
the N domain and six in the C domain, and it was this fact that delayed the solution of a 
crystal structure of ACE until recent years, since glycosylation is known to hinder the 
formation of a crystal lattice due to the flexibility and heterogeneity of glycoforms on the 
protein surface (Rogg et aI., 2002; Mehndiratta et al., 2004). It was thus necessary to reduce 
glycosylation prior to crystallisation. 
Structures have been solved of minimally glycosylated tACE (Protein Data Bank code (PDB 
ID), 10SA; equivalent to the C domain) and of the N domain (PDB ID, 2C6N), expressed in 
the presence of glucosidase I inhibitor N-butyl-deoxynojirimycin to enforce uniform 
glycosylation O'Jatesh et al., 2003; Gordon et al., 2003; Corradi et aI., 2006). In addition, the 
technique of eliminating N-linked glycosylation sites by point mutation has yielded 
glycosylation-deficient tACE mutants having two (tACE-G13; PDB ID, 2IUL) and four 
(tACE-G 1234; PDB ID, 2IUX) glycosylation sites, which are well folded and can be 
crystallised reproducibly in the same space group as the minimally glycosylated wild-type 
(Gordon et aI., 2003;Watermeyer et al., 2006). 
From these structures it can be seen that all of the potential N-linked glycosylation sites are on 
the surface, with the exception of the C-terminal site on the N domain, however it is unlikely 
that this site could be glycosylated. Glycan residues could be built into the structures at some, 
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contacts, possibly playing a role in stabilising the protein fold as wen as the crystal lattice 
structure (Watenneyer et al., 2006). 
1.5.2. Structure overview 
The crystal structures of the N and C domains of ACE share a high degree of structural 
homology. Each ACE domain is globular, consisting mostly of a-helices with a few p-sheets 
and 3w-helices (Figures 1.1, 1.2 and 1.3). The CATH database 
(http://cathwww.biochem.ucl.ac.uk) divides an ACE domain into three subdomains (Figures 
1.1 and 1.2). 
Subdomain 1 is small and mainly a-helical, comprising the so-called "lid helices" a1 and a2, 
together with 31O-helix HI and a3 (tACE residues 40-121). al and a2 fonn an up-down 
bundle connected by a hairpin bend, while HI and a3 pack against al and a2 in a helix-turn-
helix motif (Figures 1.1 and 1.2). 
Subdomain 2 is a large, complex, mainly a-helical orthogonal bundle with homology to 
domain 3 of neurolysin. It comprises 13 a-helices, five 31O-helices and four p-strands in two 
regions of consecutive residues, 122-291 and 439-617 (numbered according to tACE). The 
core of the sub domain is fonned by four long (up to 33 residues) a-helices; a8 and a20 on the 
protein surface are orthogonal to a IS and a 17, which line the active cleft. This core is flanked 
on one side by an up-down bundle comprising a4, as and a6, which packs against the lid 
helices. Helices a4 and as together fonn one half of the bundle, broken in the middle by a p-
hairpin fonned by PI and p2. Also surrounding the core are the shorter helices a7, a9, a16, 
a18, a19, H4, H6 and H7 and two short p-strands, p3 and p6. a17, a18, a19 and H7, together 
with helices from subdomain 3, fonn the floor of the active cleft. Two chloride ions are 
bound by subdomain 2. One chloride binding site (CLl) lies between the a41aSla6 bundle 
and the core of sub domain 2, and is fonned by H6, a16, a6, and loops P6-H6 and p3-H4. The 
N -tennini of a 14 and a 17, together with a7, fonn the second chloride binding site (CL2). 
Subdomain 3 is a small mixed a and P domain comprising al0, all, a12, al3, a14, HS, P4 
and pS (tACE residues 292-438). Together with subdomain 1, this domain fonns a 3-1ayer 
apa sandwich. The first layer is contributed by a 1 of sub domain 1, the middle layer by the p-
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making up the catalytic zinc-binding site; and with all, which IS on the surface of the 
molecule. 
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Figure 1.1. Sequence of human tACE, showing secondary structural elements. Residues in subdomains 1,2, 
and 3 are coloured cyan, dark blue and pink, respectively. Secondary structural elements are labelled according 
to Natesh et aI., 2003; a = a-helices; p = p-strands, H = 3w-helices. Zinc ligands are highlighted green, 
chloride-binding residues are highlighted orange (CLl) and red (CLI2), lisinopril-binding residues are 















Figure 1.2. Cartoon representation of the three-dimensional structure of tACE (PDB-ID I08A), showing CATH 
domain classification. A and B are related by a 1800 rotation about the vertical, with A showing subdomains I 
and 3 in colour, and B showing subdomain 2 in colour. Loop regions are coloured green, ~-strands are coloured 
yellow, and helices are coloured according to subdomain: the lid helices (subdomain I) are coloured cyan, the 
large a-helical orthogonal bundle (subdomain 2) is dark blue and the ~-sandwich (subdomain 3) is red. The 
catalytic zinc ion and chloride ions are shown as black and magenta spheres, respectively. Secondary structure 
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The zinc-binding site is buried at the bottom of a deep cleft between subdomain 3 and the 
large subdomain 2, which effectively divides the globule in half (Figure 1.3). The cleft is 
closed off further by the lid helices which form subdomain 1. This domain organisation 
explains the specificity of ACE for short peptide substrates, since larger folded proteins would 
not be able to access the buried active site. Openings connecting the solvent to the active cleft 
are present in the structures, but these are narrow and whiJe the active site is solvent-
accessible, it is unclear how a bulky peptide substrate could gain access (Sturrock el at., 
2004). 
Figure 1.3. Cartoon representation of hwnan tACE (PDB ID I08A), in stereo, showing the active zinc ion 
buried in a cleft between subdomains 2 and 3. The secondary structure elements are coloured according to 
subdomain, as in figure 1.2. The zinc ion is shown as a black sphere, and the chloride ions as magenta spheres. 
The inclusion of much of the linker region in the N domain crystal structure allows for 
conjecture as to the position of the C domain relative to the N domain (Corradi el al., 2006), 
although these suggestions rely on the assumption that the linker retains its native 
conformation in the crystal structure despite the absence of the C domain. Observations that a 
degree of interdomain cooperativity is involved in the cleavage of some substrates (Marcic et 
al., 2000; Binevski et al., 2003; Georgiadis el al., 2003; Woodman et at., 2005) support a 
close association between the active sites rather than a more extended configuration. Based 
on this model, the flexible loop region C128-C136 in the N domain with close proximity to 
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glycan chains on the lid helices of the C domain, or with a portion of the C domain surface 
(Figure 1.4; Corradi et aI., 2006). 
N 
Figure 1.4 Possible arrangements of the N and C domains, based on the N domain and tACE crystal structures. 
Figure taken from Corradi et al. (2006). The N domain is in a similar orientation to Figure 1.3, with subdomains 
1 and 3 coloured pink and subdomain 2 grey. The linker region is coloured red and the flexible loop C128-C 136 
dark blue. Glycan residues that were detected in the crystal structures are shown in dark green and light green 
sphere representation for the Nand C domains, respectively. 
1.5.3. Chloride ions in the structure of ACE 
Two chloride ions are present in the structures of the C domain, which has been shown to be 
activated by chloride, although the mechanism of activation is not clearly understood (Wei et 
aI., 1991). One of the chloride ions (CLl) is coordinated by R186 (NE1)l, W485 (NE), R489 
(NIH) and a water molecule, and the other (CL2) is coordinated by R522 (NE), Y224 (OH) 
and a water molecule. Both sites are surrounded by a "shell" of hydrophobic residues. The 
CLl site is 20 A from the zinc ion, separated from the substrate C terminus by the side chains 
of W279, K511 and Q281, which playa crucial role in substrate docking. It has been 
I tACE numbering is used for all references to C domain residues in this section since this numbering is used in 
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proposed that the function of this chloride ion is to position K511 correctly for substrate 
binding (Tzakos et al., 2003). The CL2 site is closer to the zinc ion (10 A) than the CLI site, 
and separated from the active cleft only by R522, which has been shown to be crucial for 
chloride dependence (Liu et aI., 2001). This chloride site has been suggested to hold the 
active site in the correct conformation for substrate binding, possibly by pulling Y520 and 
Y523 into position to interact with the substrate, or by preventing R522 from interfering with 
substrate binding by holding it in place (Tzakos et aI., 2003; Sturrock et al., 2004). 
In the N domain, which is not activated by chloride ions to as great a degree as the C domain 
(Wei et al., 1991), R186 of the CLI binding site is replaced by H164 and no chloride ion was 
detected at this site in the N domain crystal structures. The CL2 site is conserved in the N 
domain and contains a bound chloride ion in the N domain crystal structures. 
Tzakos and co-workers (2003) identified a putative conserved chloride ion channel for CL2 
with homology to the Salmonella enterica serovar typhimurium CLC chloride channel, and 
proposed that these residues perform a similar function in ACE, creating an electrostatically 
favourable environment for chloride binding. They also proposed that E403 serves as an ion 
gate in the C domain, and that its replacement with R3 81 in the N domain is the reason for the 
lower chloride requirement of this domain. However in contrast to CLC, which is a 
membrane channel protein, the CL2 ion site of ACE is partially exposed to the external 
milieu; moreover the proposed channel residues are arranged in different orientations to those 
of the CLC ion channel, suggesting only the loosest functional conservation. 
1.5.4. The structure of the active site 
The catalytic zinc ion is located approximately in the centre of the molecule, at the bottom of 
the active cleft, forming a bottle-neck between a smaller substrate C-terminus binding 
chamber and a larger N-terminus binding chamber. Co-crystal structures with lisinopril (N 
and C domains), captopril and enalaprilat (C domain only) allowed the identification of the 
residues involved in substrate binding (Natesh et aI., 2003; Natesh et aI., 2004; Sturrock et aI., 
2004; Corradi et aI., 2006). In addition, a co-crystal structure of tACE with the C-domain-
selective inhibitor RXP A380 has shed light onto the residues important for domain-selectivity 
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Active site interactions in the co-crystal structures are presented in Appendix B, and residues 
within 6 A of any of the inhibitors (captopril, lisinopril, enalaprilat and RXP A380) in the 
active sites of the N and C domains are compared in Table 1.5. All the inhibitors take on 
similar extended conformations in the active site, and the conformation of lisinopril does not 
change significantly between the N and C domains. 
Table 1.5 Residues within 6 A of bound inhibitor in the crystal structures of ACE, showing their participation in 
inhibitor binding subsites. Highlights indicate residues that differ between the domains. 
N domain tACE (C domain) Subsite 
Q259 W 279 (855) S2': C tenninus binding site 
Q259 Q281 (857) S2' 
S 260 T 282 (858) S2' 
0354 E 376 (952) S2' 
S 357 V379 (955) S2' 
H 361 H 383 (959) S2' and zinc ligand 
0393 0415 (991) S2' 
E 431 0453 (1029) S2' 
K432 K454 (1030) S2' 
F 435 F 457 (1033) S2' 
F 438 F 460 (1036) S2': C-tenninus binding site. 
K489 K 511 (1087) S2': C-tenninus ligand 
y 498 Y 520 (1096) S2': C-tenninus ligand 
Y 501 Y 523 (1099) S2' 
F 505 F 527 (1103) S2' 
T358 V 380 (956) S2'/SI ' 
0140 E 162(738) SI ' 
H 331 H 353 (929) SI ' 
A332 A 354 (930) S 1 ' 
Q 355 0377 (953) SI ' 
H 491 H 513 (1089) SI ' 
E 362 E 384 (960) S 1': ligand of zinc-binding oxygen atom 
Y 501 Y 523 (1099) S 1 ': ligand of zinc-binding oxygen atom 
043 N 70 (646) SI 
S 119 E 143 (719) SI 
S333 S 355 (931) SI 
E 389 E 411 (987) S 1 and zinc ligand 
F 490 F5l2(1088) SI 
N 494 S 516 (1092) SI 
T496 V 518 (1094) SI 
W335 W 357 (933) S1/S2 
R 500 R 522 (1098) S I/S2 
Y 338 Y 360 (936) S2 
A 334 A 356 (932) S2 
D 336 D 358 (934) S2 
H 365 H 387 (963) S2 and zinc ligand 
Y 369 F 391 (967) S2 
Y 372 Y 394 (970) S2 
R380 R 402 (978) S2 
R 381 E 403 (979) S2 
G382 G 404 (980) S2 
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The inhibitors bind to the active site zinc ion via their respective zinc binding groups; 
carboxyalkyl carboxylates in the case of lisinopril and enalaprilat, a sulphydryl group in 
captopril and a phosphinate in RXP A380. Comparison between the co-crystal structures of 
tACE with lisinopril, captopril and enalaprilat revealed a correlation between inhibitor 
potency and the number of polar protein-inhibitor interactions observed (Natesh et al., 2004). 
Binding affinity is also strongly influenced by the strength of the zinc-binding groups, with 
the sulphydryl of captopril being stronger than the carboxylate of lisinopril and enalaprilat 
(Redelinghuys et ai., 2005). 
The inhibitor C-terminal carboxylate interacts with a positively-charged patch formed by 
Y520, Q281 and K511, interactions which are thought to be important in determining the 
correct positioning of the substrate scissile bond at the active site (Kim et aI., 2003; Sturrock 
et aI., 2004; Naqvi et al., 2005). This would explain why ACE can act as a tripeptidase or 
endopeptidase on substrates with ami dated C-termini (Naqvi et aI., 2005). 
1.6. ACE reaction mechanism 
A general base mechanism of catalysis is thought to be conserved in zinc metalloproteases 
having a HEXXH zinc-binding motif, based on extensive catalytic and structural studies of 
related enzymes thermo lysin and carboxypeptidase A, among others (Lipscomb & Strater, 
1996; Pelmenschikov et aI., 2002; Tzakos et al., 2003). In ACE, the following details of the 
mechanism have been proposed (Figure 1.5; tACE numbering; Tzakos et a!., 2003; Sturrock 
et aI., 2004): 
When no ligand is bound, the active site zinc ion is tetrahedrally coordinated by the two His 
side chains (H383 and H387) and downstream Glu (E411) of the HEXXH + E motif, with a 
water molecule or hydroxide ion as the fourth ligand, in an arrangement such as that seen in 
the unliganded structure of the N domain (PDB ID 2C6F). As a peptide substrate binds, its 
scissile carbonyl oxygen interacts with the zinc as a fifth ligand, forming a Michaelis 
complex. This arrangement displaces the zinc-bound water molecule towards E384 of the 
HEXXH motif, where it becomes strongly polarised between the positively charged zinc ion 
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Nucleophilic attack occurs, with the water being deprotonated by E384, and results in the 
fonnation of a tetrahedral transition state. In this state, the scissile carbonyl group has been 
converted to a negatively-charged geminal diolate (gem-diol) intennediate with two 
covalently bound oxygens. The proton from the attacking water is transferred by E384 onto 
the scissile amide nitrogen, and the intennediate quickly decomposes with peptide bond 
breakage, into carboxyl and amino leaving groups. These leaving groups are likely to be 
similar to those observed in the crystal structure of Escherischia coli ACE homologue 
dipeptidyl carboxypeptidase (Dcp), which was co-crystallised with the products of slow 
cleavage of a peptide inhibitor still bound in the active site (Comellas-Bigler et al., 2005). 
The transition state is stabilised by interactions with conserved residues H331/353, A332/354 
and Y501l523 (N domainitACE numbering). 





carboxylate Product Release 




Nucleophilic Water Attack 






Figure 1.5 Proposed general base catalysis mechanism for ACE. Figure adapted from Pelmenschikov et al. 
(2002), with numbering for tACE. In the free enzyme (1) the zinc ion is tetrahedrally coordinated by H383, 
H387, E4Il and a water molecule. A substrate docks into the active site forming a Michaelis complex (2) in 
which the zinc-bound water molecule is polarised between E384 and the zinc ion. The Michaelis complex is 
converted to a tetrahedral transition state (3) upon nucleophilic attack of the carbonyl carbon by the zinc bound 
water. The intermediate decomposes with bond breakage and product release, returning via an enzyme-
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1. 7. Structures of sequence homologues of ACE 
1.7.1. Angiotensin-converting enzyme 2 
Angiotensin-converting enzyme 2 (ACE2) is a recently-discovered mammalian homologue of 
ACE with its own distinct genetic locus (Tipnis et aI., 2000; Donoghue et al., 2000). It is 
expressed in the heart, kidneys, testes and gastrointestinal tract and is in itself an interesting 
potential drug target, as it has been implicated in the regulation of cardiac function and the 
RAS (reviewed by Warner et al. (2004». Moreover ACE2 has recently been shown to be the 
membrane receptor for the SARS coronavirus. This two-domain enzyme has an ACE-like 
domain with 42% sequence identity to the N domain of human ACE and a C-terminal domain 
with 48% identity to human collectrin (Warner et al., 2004). The ACE domain of ACE2 acts 
as a carboxypeptidase, removing a single amino acid from the C-terminus of a number of 
peptide substrates, including neuropeptides and RAS and KKS-related peptides, some of 
which are also cleaved by ACE (Turner et aI., 2002). 
Structures of unliganded and inhibitor-bound ACE2 have been solved recently (PDB ID lR42 
and lR4L; Towler et al., 2004), revealing close structural homology between ACE and the 
ACE domain of ACE2, however only fragments of the collectrin-like domain were defined in 
the crystal structures. The monopeptidase activity of ACE2 is explained by the observation 
that the P2' pocket of this enzyme is occluded by an arginine side chain (Guy et aI., 2003; 
Towler et al., 2004). Interestingly, in the unliganded ACE2 structure, the smaller 
subdomains 1 and 3 (the lid helices and adjacent ~-sandwich) are hinged away from 
subdomain 2 (the larger zinc-binding orthogonal bundle), with residues at the outer edges 
moving apart by 20 A relative to the closed state (Figure 1.6 (B); Towler et aI., 2004). 
1.7.2. Insect ACE structures 
Six ACE homologues occur in the fruit fly, Drosophila melanogaster, of which two, the 
single-domain enzymes AnCE and ACEr, have thus far been shown to encode active 
metallopeptidases with similar substrate specificity and inhibitor sensitivity to ACE (Williams 
et al., 1996; Bingham et al., 2006). A crystal structure of AnCE has been solved (PDB ID 
1J38; Kim et al., 2003), revealing close structural identity with the human enzyme, as 
expected from the high degree of sequence identity (41 % and 42% to the N and C domains of 
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the active site (PDB ID 1136, 1137), revealing almost identical modes of substrate binding to 
those seen in the active site oftACE (Kim et aI., 2003). 
1.8. Structural homologues of ACE 
1.8.1. Structural classification of ACE and ACE homologues 
The ACE fold is classified by the SCOP database (Structural Classification of Proteins; 
http://scop.mrc-lmb.cam.ac.ukJscopD as being of the class "a. and W' (having mainly 
antiparallel ~-sheets with segregated a. and ~ regions), with a "zincin-like" fold (containing 
mixed ~-sheet with connections over the free side of the sheet), belonging to the 
"metalloproteases" ("zincins") catalytic domain superfamily and "neurolysin-like" family. 
This structural family includes the M2, M3 and M32 families of metalloproteases having a 
multihelical N-terrninal half and a C-tenninal thennolysin-like catalytic domain. 
The classification of zinc metalloproteases has been reviewed extensively elsewhere (Hooper, 
1994; Rawlings & Barrett, 1995; Spyroulias et aI., 2004), however it should be noted that the 
grouping of families and superfamilies has changed considerably in recent years as more 
structural infonnation has become available, and is unlikely to remain static in the future. 
Briefly, according to the most recent review (Spyroulias et aI., 2004), the "zinc ins" include all 
metalloproteases containing the HEXXH zinc-binding motif, and this group can be sub-
divided into "gluzincins", in which and third zinc ligand is a downstream glutamate, and 
"metzincins", which contain a conserved active site methionine. Within these major 
subdivisions, metalloproteases are grouped according to sequence conservation and active site 
structure (a complete list of families is available in the MEROPS database, 
http://merops.sanger.ac.uk), with the M2 family containing ACE-related enzymes, the M3 
family comprising metalloproteases with homology to thimet oligopeptidase, and the M32 
family having homology to carboxypeptidase Taq from Thermus aquaticus. 
According to the SCOP database, other members of the "neurolysin-like" family for which 
structures have been detennined are rat neurolysin and thennostable carboxypeptidase 1 from 
Pyrococcus furiosus (PfuCP) (Table 1.6; Figure 1.6 (C,G)). NCBl's macromolecular 
modelling database (MMDB) lists several additional structure neighbours of ACE, namely 
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stearothermophilus (OligoF), and carboxypeptidase 1 from Thermus thermophilus (ThCP) 
(Table 1.6; Figure 1.6 (E,F,H)). Although these enzymes come from diverse sources and have 
negligible sequence identity, they share a high degree of structural homology (Appendix C). 
Table 1.6 Structural homologues of ACE in the Protein Data Bank, showing sequence identity. 
ACE homologue; source Enzyme PDBID Identity (%). 
family 
ACE2; Homo sapiens M2 lR4F, IR4L 42 
AIlCE; Drosophila melanogaster M2 1]36, 1J37, 1J38 41 
neurolysin; Rattus norvegicus M3 IIL1 NID 
thimet oligopeptidase; Homo sapiens M3 IS4B NID 
dipeptidyl carboxypeptidase (Dcp); Escherichia coli M3 lY79 NID 
oligoendopeptidase F (OligoF); Bacillus stearothermophilus M3 2HLN,2HLJ NID 
carboxypeptidase I (ThCP); Thermus thermophilus M32 lWGZ NID 
thennostable carboxypeptidase I (PfuCP); Pyrococcus furiosus M32 1KA2,lKA4, NID 
lK9X 
a % sequence identity with the N domain of human ACE, determined by pair-wise BLAST using the 
BLOSUM62 matrix (http://www.ncbi.nlm.nih.govlblastfb12seq/wblast2.cgi). NID: no identity detected. 
1.8.2. Thimet oligopeptidase, neurolysin and Dep 
Neurolysin and its close homologue thimet oligopeptidase (60% identity) are well-
characterised mammalian oligopeptidases of the M3 family. Their activity profiles are 
similar, both having endopeptidase activity on a broad range of peptide substrates. Both are 
active as monomers, a d rat thimet oligopeptidase forms inactive oligomers by disulphide 
bond formation under oxidising conditions (Ray et aI., 2004). The best-understood role of 
neurolysin is the inactivation of the I3-residue neuropeptide neurotensin, by removal of a C-
terminal tripeptide (Brown et aI., 2001). Thimet oligopeptidase degrades peptides released by 
the proteasome (Ray et aI., 2004). Differences in electrostatic conditions on the floor of the 
active site, which are contributed largely by a single a-helix, correlate to the differences in 
activity between the two enzymes (Ray et aI., 2004; Lim et aI., 2007). The presence of 
flexible loop regions in the active cleft is thought to allow the active site to adapt to 
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D 
H 
Figure 1.6 Structural homologues of ACE; cartoon represeotation showing subdomain structure and hinging 
about the active cleft. (A) hwnan tACE (PDB ID 1086), (B) ACE domain of unliganded human ACE2 (PDB ID 
I R42), (C) rat neurolysin (PDB ID I ILl), CD) hwnan thimet oligopeptidase (PDB ID I S4B), (E) E. coli 
dipeptidyl carboxypeptidase (PDB ID I Y79), CF) B. stearothermophilus oligoendopeptidase F (PDB ID 2HLN), 
(G) Pyrococcus furiosus carboxypeptidase I (PDB ID I KA2) and (H) Thermus thermophilus carboxypeptidase I 
(PDB ID 1 WGZ). Subdomains I, 2 and 3, identified by alignment with tACE, are coloured blue, yellow and red 
respectively. Zinc (magnesium in the case of (G» and chloride ions are shown as grey and green spheres, 
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Dcp from Escherichia coli is another M3 zinc metallopeptidase, having 25% identity to 
neurolysin. Despite its low sequence identity to ACE, it has similar activity, acting as a 
dipeptidyl carboxypeptidase on ACE substrates and binding to ACE inhibitors (Comellas-
Bigler et a!., 2005). Dcp is active as monomer in the cytoplasm where it catalyses the 
degradation of intracellular peptides (Comellas-Bigler et a!., 2005). 
1.8.3. Thennostable homologues 
OligoF, PfuCP and ThCP are all thermostable metallopeptidases, of interest due to their 
potential as industrial enzymes because they are active at temperatures close to 100°C. 
PfuCP and ThCP are both members of the M32 family and share 35% identity, originating 
from archaea and bacteria respectively (Nagata et al., 2004; Gerdts et a!., 2006), while OligoF 
is a bacterial M3 endopeptidase. PfuCP differs from other zincins in requiring a non-zinc 
metal cation such as cobalt for optimal activity, and in the formation of an active homodimer 
joined by a four helix bundle made between the lid helices of two monomers (Arndt et a!., 
2002). 
1.8.4. Conserved activity among structural homologues 
These structurally similar enzymes from diverse sequence groups also share a selectivity for 
unfolded oligopeptide substrates, probably a result of the buried nature of their active sites 
(Brown et aI., 2001), as well as the ability to cleave a broad range of sequences. Peptide 
substrates are predicted to associate with the active cleft by formation of an twisted 
antiparallel ~-sheet with the "edge-strand" of a conserved active site ~-sheet in subdomain 3 
(Comellas-Bigler et al., 2005). This mode of substrate binding has been observed to be 
common to almost all proteases (Tyndall et a!., 2005). The registration of peptides at the 
active zinc ion is determined by the size and charge of the substrate N- and C-terminus 
binding pockets (Brown et al., 2001; Ray et aI., 2004; Comellas-Bigler et a!., 2005). 
1.8.5. Hinging about the active cleft 
Although the active site is buried in a deep cleft in all cases, the degree of closure differs from 
structure to structure and from one crystal form to another (Figure 1.6; Ray et al., 2004). For 
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but the liganded structure ofDcp is considerably (~ 12 0 rotation) more closed about a similar 
hinge axis to that observed in ACE2 (Comellas-Bigler et al., 2005). Thimet oligopeptidase 
also exhibits a slight hinge displacement relative to neurolysin (Ray et aI., 2004). Similar 
hinging could be predicted for unliganded ACE2 and a modelled open form of ACE by 
normal mode analysis and is thus probably an intrinsic feature of this type of fold 
(Watermeyer et a!., 2006). 
Crystallographic atomic displacement parameters (temperature factors; Watermeyer et al., 
2006), the preferential binding of monoclonal antibodies to liganded, over unliganded, N 
domain (Skirgello et aI., 2006), and calorimetric studies that revealed a large entropic 
component to substrate binding (Andujar-Sanchez et al., 2004), are also consistent with a 
closing active site model for ACE. 
1.9. Structure-based design of ACE inhibitors 
1.9.1. Structural detenninants of domain-selectivity 
The 55% identity of the N and C domains of ACE is not evenly distributed throughout the 
structure. For example, the lid helices (N domain 22-73 and C domain 613-675) are only 
30% identical, while the residues between the zinc-binding HEMGH motif and downstream E 
(N domain 361-389 and C domain 904-932) are 86% identical (Appendix A). 
Comparison of the crystal structures of tACE (C domain) and the N domain reveals 69% 
identity for the 42 residues within 6 A of the inhibitors captopril, lisinopril, enalapril and 
RXP A380 (Table 1.5). If one excludes from this comparison zinc ligands, residues that bind 
the substrate C-terminal carboxylate, and residues that interact with substrate via backbone 
atoms, the overall sequence identity is only 51 %, with nine of the thirteen variations occurring 
in the S2' and Sl subsites (Table l.5). 
1bis variation is reflected in the difference in affinity (Ki) of lisinopril for each domain in 
isolation (Table 1.3). For example, the slight C-domain-selectivity oflisinopril is thought to 
be the result of the substitution oftACE residues E162 and D377 with D140 and Q355 in the 
SI' pocket of the N domain, which reduces the number of protein-inhibitor hydrogen bonds 
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S2 and S2' pockets of tACE with the more polar Y369, S357 and T358 in the N domain was 
proposed to account for the marked domain-selectivity of RXPA380, based on the tACE co-
crystal structure (Corradi et aI., 2007). 
1.9.2. Design of novel domain-specific ACE inhibitors 
The domain-selectivity of ACE suggests a new direction for structure-based drug design. 
Although numerous ACE inhibitors are available for clinical use, these are not without 
undesirable side effects, which can include persistent cough, anaemia, impaired renal 
function, and potentially life-threatening angioedema (Sica, 2004). Elevated levels of BK 
and other peptides have been associated with ACE inhibitor-related cough and angioedema, 
implicating the inhibition of cleavage of non-AI peptides in the onset of these symptoms 
(reviewed by Acharya et al. (2003». 
The situation is made more complex by the observed domain cooperativity in the cleavage of 
some substrates in vitro (Binevski et al., 2003; Georgiadis et al., 2003; Andujar-Sanchez et 
al., 2004), as well as by the presence of local tissue RAS and the differential effects of AI 
signalling via two receptors (reviewed by Zaman et a!. (2002), Acharya et a!. (2003) and 
Fleming et al. (2006». However, the recent observations that the C domain of ACE is 
largely responsible for the cleavage of AI in mice, in vivo, while BK cleavage can be carried 
out by either domain (Fuchs et a!., 2004; Fuchs et a!., 2007), strengthens the idea that a C 
domain-specific ACE inhibitor might have a different clinical profile from the currently 
available treatments, possibly eliminating some of the side effects common to ACE inhibitor 
therapy today, 
1.9.3. Aims of this study 
Two sets of inhibitors have recently been designed and synthesised based on known domain-
specific inhibitors keto-ACE (hereafter referred to as kAP) and lisinopril (Redelinghuys et al., 
2006; Nchinda et al., 2006a; Nchinda et a!., 2006b). Of the sets of derivatives, two of the 
ketone inhibitors, kA W and kAF, and a lisinopril-derivative, lisW, all derived from their 
parent compounds by P2' substitution, were found to be strongly selective for the C domain 
(Redelinghuys et a!., 2006; Nchinda et a!., 2006a), The aim of this study is to determine x-
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selective inhibitors, in order to determine their mode of binding, thereby gammg an 
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2.1. Preparation of the protein sample 
2.1.1. Minimally glycosylated tACE construct 
A minimally glycosylated human tACE mutant, tACE-G 13, was used as a C domain 
equivalent for X-ray crystallographic studies. This mutant was generated previously by 
deletion of the N-terminal O-glycosylated 36 residues of tACE, and elimination of all but the 
first and third N-glycosylation sites by Asn-Gln point mutation (Figure 2.1; Gordon et at., 
2003). tACE-GI3 has previously been shown to be reproducibly crystallisable and to have an 
identical conformation to minimally glycosylated wild-type tACE (Watermeyer et ai., 2006). 
N.Glycosylation saquon no: 123 " 5 6 1 sheddase 
1 36 12 90 109 155 331 586 620 1M 
tACE NH2 .--........ --IIIIII--I ____ ---IIIIIII----IIIIIH H-iIII-- COOH 
tACE-Gi3 NH2 -----------~ H""---COOH 
Figure 2.1 Schematic diagram of tACE constructs, showing wild-type tACE and tACE-G13, the minimally-
glycosylated construct used for crystallisation. Full-length wild-type tACE has an N-terminal O-glycosylated 
region (grey box), six N-glycosylation sites (filled squares), one non-glycosylated N-glycosylation sequon (open 
square), and a C-terminal transmembrane domain (TM). tACE-G13 lacks the O-glycosylated region and has 
only two intact N-glycosylation sites. Expressed protein is shed into the medium by a sheddase that cleaves 
between Arg 627 and Ser 628. 
2.1.2. Expression 
A stably transfected Chinese hamster ovary cell line expressing the tACE-G 13 construct from 
the vector pLEN-tACE~36-g13 (Gordon et ai., 2003) was used to produce protein for 
crystallisation. Cells were grown to confluence in 10% FCS medium (50% DMEM 
(Highveld Biological, South Africa), 50% Ham's medium (Highveld Biological, South 
Africa), supplemented with 10% heat-inactivated foetal calf serum (Invitrogen Life 
Technologies, United Kingdom)). Expression was induced with 40 11M ZnClz in 2% FCS 
medium (50% DMEM, 50% Ham's medium supplemented with 2% heat-inactivated foetal 
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medium by the action of an endogenous sheddase between R627 and S628 (Figure 2.1; Ehlers 
et al., 1996). 
2.1.3. Purification 
Soluble tACE-G 13 was purified from culture medium by lisinopril affinity chromatography, 
as described previously (EWers et aI., 1989; EWers et aI., 1991; Gordon et aI., 2003). Briefly, 
cell culture medium containing shed tACE-G 13 was applied to a Sepharose-28-lisinopril 
affinity column and unbound protein was eluted with 0.5 M NaCl, 20 mM Hepes at pH 7.5. 
Bound tACE-G 13 was eluted as a single peak (detected by measuring the absorption at 280 
nm) using 50 mM borate at pH 9.5. Peak fractions were assayed for ACE activity and 
fractions containing ACE were pooled, dialysed against 2 L of 0.5 mM Hepes (PH 7.5) 
overnight and concentrated to between 1 and 5 mg/ml using an Amicon Ultra-4 spin column 
(Millipore ). 
The protein concentration in purified samples was determined by a Bradford protein assay 
(Bio-Rad protein micro-assay). Concentrated samples were shown to contain a single purified 
species of the correct molecular weight (~ 70 kDa) by 10% denaturing SDS-P AGE with 
Coomassie staining. 
2.1.4. ACE activity assay 
ACE activity in the harvested medium, elution peak fractions, column flow-through and 
dialysate was determined by measuring the hydrolysis of Hippuryl-His-Leu (Sigma) in a 
fluorirnetric assay (Friedland & Silverstein, 1976; Schwager et aI., 2006) as follows. Samples 
were incubated for 15 minutes at 37°C in the presence of 5.65 mM Hippuryl-His-Leu, 5.2 
mM NaOH, 0.052 M Hepes (PH 7.5) and 0.31 M NaCl. The hydrolysis reaction was stopped 
by the addition of 750 ~l of 0.28 M NaOH. This mixture was then incubated at room 
temperature for ten minutes in the presence of 8 mM o-phthaldialdehyde, allowing the 
formation of the fluorescent adduct of o-phthaldialdehyde and L-His-L-Leu. 3 N HCI (100 
~l) was added to stop the reaction, and the amount ofL-His-L-Leu present was determined by 
fluorimetric analysis (excitation wavelength, 360nm; emission wavelength, 485nm) and 
comparison of the fluorescence with that ofL-His-L-Leu standards. 1 mU of ACE activity is 
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2.2. Preparation of inhibitor samples 
kAP-derived inhibitors (SS)-S-[(N-benzoyl)amino]-4-oxo-6-phenyl-hexanoyl-L-tryptophan 
(kA W) and (SS)-S-[(N-benzoyl)amino ]-4-oxo-6-phenyl-hexanoyl-L-phenylalanine (kAF), as 
well as lisinopril-derivative (SR)-I-(N(2)-(1-carboxy-3-phenylpropyl)-L-Iysyl)-L-tryptophan 
(lisW), were synthesised previously (Nchinda et al., 2006a; Nchinda et al., 2006b). 
Stocks for crystallisation trials were made by dissolving the lyophilised inhibitors in water, or 
in a small volume of DMSO and then diluting in water, where necessary. Trials were carried 
out using solutions of the two separated enantiomeric forms of lisW, lisW-S and lisW-R, 
differing in the chirality of the PI alpha carbon. 
2.3. Crystallisation 
Co-crystallisation trials were carried out at a range of conditions based on the crystallising 
conditions for tACE-G 13 (Watermeyer et aI., 2006). 
Various concentrations of inhibitors were pre-mixed with 2-S mg/ml tACE-G13 (in S mM 
Hepes, pH7.S), and 2 I.d of these mixtures were added to 2 III reservoir buffer in 
crystallisation drops. Hanging drop experiments were carried out at 16 °C, over 1 ml 
reservoirs comprising S-20 % PEG 4000, 10 IlM ZnS04, 10-200 mM sodium acetate, pH 4.0-
6.S. To prevent condensation on the cover slides, buffers were chilled to 4 °C before setting 
up trials, and wells were covered with SOO III of oil (3 parts paraffin, 2 parts silicon oil, 
Hampton; Chayen, 1997). All buffers were filtered at 0.22 IlM. 
For seeding experiments, inhibitor-free microcrystal seeds were grown in drops containing 
l.4S mg/ml tACE-Gl3 over a reservoir containing 10 mM sodium acetate pH 4.7 (Merck), IS 
% PEG 4000 (Fluka), 10 IlM ZnS04. An eyelash was used to streak seeds into fresh drops 
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2.4. Data collection and processing 
2.4.1. Data collection 
Crystals were transported in their hanging drops to beamline BM14(UK) of the European 
Synchrotron Radiation Facility, Grenoble, France. From the drops, suitable crystals were 
mounted in loops with magnetic bases, dipped briefly in cryo-protectant (20% glycerol, 80% 
reservoir buffer), plunge-frozen in liquid nitrogen and stored in labelled vials containing 
liquid nitrogen. These vials were inserted into a cartridge for handling by the robotic data 
collection apparatus. 
Data were collected at 100 K from a single crystal per inhibitor, using a single wavelength of 
1.033 A with a maximum intensity of ~7.5 x lOll photons. The beam had a focal area of 0.25 
rom2• Diffraction images were recorded on a MARMOSAIC225 charge-coupled detector, and 
had an area of225 rom x 225 rom. Data collection statistics are presented in Chapter 3, Table 
3.2. 
2.4.2. Data processing and phase determination 
Data were processed using HKL2000 (Otwinowski & Minor, 1997). Phasing was carried out 
by molecular replacement (MR) with EPMR 2.5 (Kissinger et ai., 1999) using protein atoms 
from the crystal structure oftACE-G 13 (PDB ID 2IUL) as a model. 
Model building was carried out using 0 v9.0.7 (Jones, 1978). Model building involved 
identification, insertion and adjustment of the inhibitor molecules, minor adjustment of some 
protein side chains and surface loops, as well as addition of ions and water molecules. In 
order to minimize model bias, O'A-weighted composite omit maps, calculated with simulated 
annealing (5% omission) using CNS (Brunger et ai., 1998) were used for the initial manual 
building and for much of the subsequent rebuilding, in addition to O'A-weighted 2Fobs-Fcalcand 
Fobs-Fca/c maps. The CNS water ~ick protocol (Brunger et al., 1998) was used to add water 
molecules, followed by visual inspection. Glycan residues were added to the structures by 
aligning the structure of tACE-G 13 (PDB ID 2IUL) with the structure concerned and copying 
the coordinates of the glycans where clear density was present in all maps. Glycan residues 
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built using PRODRG (Schiittelkopf & van Aalten, 2004) and ARP/wARP (Collaborative 
Computational Project, 1994) or by hand where ARP/wARP did not succeed in recognising 
ligand density. 
Maximum likelihood minimization was carried out against the working set of crystallographic 
data, using CNS (Brunger et al., 1998). In order to minimize model bias, the test set for cross-
validation was selected to consist of the same set of reflection indices as were used during the 
solution of the structure of the MR model (PDB ID 2IUL). This was achieved by using CNS 
to merge the "TEST" column (containing the randomly-generated numerical flag used for the 
selection oftest reflections) from the structure factor file that was used to solve the MR model 
structure, into the new co-crystal structure factor files. Since the MR model was of higher 
resolution than the present data, no extension of the test set was required. 
Simulated annealing refinement was used to adjust selected regions to fit the data better. 
Individual isotropic atomic displacement parameters (B-factors) were refined in later rounds 
of refinement. Where surface side chains were disordered, and no discreet conformations 
could be detected in composite omit maps, a plausible conformer was selected and B-factors 
were allowed to refine to high values. This method was chosen due to the difficulty with 
which CNS handles missing atoms in residues. 
Structure validation was carried out using PROCHECK and SFCHECK from the CCP4 suite 
(Collaborative Computational Project, 1994), as well as Molprobity (Davis et aI., 2004). 
Hydrogen bonds and close contacts were identified using HBPLUS (McDonald & Thornton, 
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3.1. Introduction 
The novel inhibitors kA W, kAF and lisW have been shown to have a high degree of 
selectivity for the C domain of human ACE (Redelinghuys et ai., 2006; Nchinda et ai., 
2006a). kA W and kAF were derived from kAP (Redelinghuys et al., 2006), and lisW from 
lisinopril (Nchinda et al., 2006a), by P2' substitution (Figure 3.1). Two enantiomers oflisW, 
lisW-S and lisW-R, were synthesised, differing in the chirality of the PI Phe alpha carbon 
(Figure 3.1). In order to elucidate the mechanism of domain-selectivity, the inhibitors were 
co-crystallised with human tACE, which has a sequence identical to that of the C domain of 
sACE. 
P/ P/ P/ 
kAP 
Oy~MQ 









:?" ~ I H 0 H OyN~N, lisW-R 
o ~o eOOH 
V 
Figure 3.1 Chemical structures of keto-ACE (kAP) and its derivatives, kA W and kAF, and lisinopril and its 
derivative, lisW, showing residue positions relative to the zinc-binding group (Pz, Pj, PI', Pz'). Both enantiomers 
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3.2. Co-crystallisation o[minimally glycosy/ated tACE with inhibitors 
Crystallographic studies were carried out using a minimally glycosylated mutant of tACE, 
tACE-G 13, lacking the N-terminal O-glycosylated region and having all but the first and third 
glycosylation sites (N72 and NI09) knocked out by Asn-Gln point mutations (Gordon et ai., 
2003). This mutant has been crystallised previously under similar conditions to those used for 
the crystallisation of minimally glycosylated wild-type tACE, in the same crystal form, and 
found to have essentially the same structure as the wild-type (Watermeyer et al., 2006). Since 
tACE differs from the C domain of ACE only in its O-glycosylated region, tACE-G 13 is 
equivalent to a minimally glycosylated C domain. 
Initial co-crystallisation trials tested conditions based on those used for crystallisation of 
tACE-G 13 in the absence of inhibitor, but including various concentrations of inhibitor pre-
mixed with the protein before setting up the drop. Crystals of similar morphology to the 
tACE-G 13 crystals obtained previously were grown in drops containing kA W (40 ,""M, with 
1.25 mg/ml tACE-G13) and the S enantiomer oflisW (51 jlM and 109 jlM, 1.5 mg/ml tACE-
G 13), however the latter were non-diffracting. Diffraction data were collected from the kA W 
co-crystals grown using this method, pr cessed to 3.0 A, and phased using molecular 
replacement, however no continuous inhibitor density was present in the active site, indicating 
that these were not true co-crystals. Since these conditions had thus failed to produce suitable 
co-crystals, progressively higher concentrations of inhibitor were included in co-
crystallisation experiments. However, higher concentrations of inhibitor, with and without a 
small amount of DMSO (0-10 %), were found to inhibit nucleation. 
During the course of these crystallisation trials, the rate of crystal nucleation in inhibitor-free 
drops was found to depend strongly on the concentration of sodium acetate, with showers of 
microcrystals forming in drops containing lower concentrations of acetate ions (Figure 3.2 
(B)). Some of these microcrystals were streaked as seeds into drops containing tACE-G 13 
and inhibitor, and co-crystals were grown within 14 days after seeding (Figure 3.2 (C)). The 
inhibition of nucleation by the presence of ACE inhibitors in the crystallisation drops was 
further demonstrated by the formation of showers of tiny microcrystals when seeds were 
streaked into inhibitor-free drops (Figure 3.2 (D)), versus the growth of fewer, larger crystals 
in the presence of inhibitors (Figure 3.2 (C)). The conditions for growth of the tACE-G 13-
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Figure 3.2 Co-crystallisation of tACE-G 13 with inhibitors by streak-seeding. All experiments shown were 4 IJ.I 
hanging drops incubated at 16°C, with a starting protein concentration of 1.45 mglml and reservoirs containing 
PEG 4000 (15%), ZnS04 (10 IJ.M) and sodiwn acetate (various concentrations), pH 4.7. (A) tACE-G\3 crystals 
grown in the absence of inhibitor, with 50 roM sodiwn acetate. (B) Microcrystals grown under the same 
conditions as in (A), but using 10 roM sodium acetate. (C) Microcrystals such as those shown in (B) were used 
as seeds to grow co-crystals such as these, grown in the presence of250 roM lisW-S. (D) If microcrystals were 
streaked into drops containing no inhibitor, excessive nucleation resulted in the formation of showers of tiny 
microcrystals. 
Table 3.1 Conditions for growth oftACE-G 13-inhibitor co-crystals from which data were collected. All crystals 
used for data collection were grown over reservoirs containing 15 % PEG 4000, 50 roM sodiwn acetate and 10 
IJ.M ZnS04, pH 4.7. 
Inhibitor Protein concentration (mglml) • Inhibitor concentration (flM) • K; Codomain (flM) b 
lisW-S 1.45 250 7.0 
lisW-R 1.45 50 26.3 
kAW 1,00 1000 0,68 
kAF 1.45 1250 0.83 
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3.3. Data collection and processing 
Diffraction data were collected from single crystals of tACE-G13 grown in the presence of 
kA W, kAF and both enantiomers oflisW, having approximate dimensions of 0.2 x 0.004 mm. 
Data collection statistics are presented in Table 3.2. The datasets obtained from crystals 
grown in the presence of lisW-S and lisW-R will be referred to as lisW-A and lisW-B 
respectively, for reasons which will become clear during the course of the discussion. 
Table 3.2: Diffraction data statistics. 
kAW kAF UsW-A UsW-B 
Resolution range (A) 43-2.18 43-2.17 43-2.40 43-2.30 
Highest resolution shell (A) 2.26-2.18 2.25-2.17 2.49-2.40 2.38-2.30 
Space group P21212\ P21212] P212121 P212]21 
Unit cell dimensions (A) 
a 59.85 60.38 60.07 56.38 
b 85.04 85.07 85.04 84.79 
c 134.92 135.51 135.09 133.96 
Unit cell volume (A3) 686667 696078 690161 640407 
No. reflections 130768 158385 186516 84906 
No. unique reflections 34837 33306 27439 26578 
Redundancy a 3.8 (3.2) 4.8(4.1) 6.8 (4.9) 3.2 (2.9) 
Completeness (%) a 95.0 (95.2) 88.3 (80.2) 99.1 (95.1) 89.9 (86.4) 
Refined detector distance (mm) 180.8 193.2 193.2 193.5 
Refined mosaicity (0) b 0.57 0.81 0.68 1.05 
<Vcr(I» a 10.9 (2.4) 14.4 (2.6) 13.86 (2.4) 12.08 (2.2) 
Rmerge (%) a, c 10.9 (42.1) 8.7 (39.2) 12.1 (44.6) 8.7 (46.5) 
aValues in parentheses refer to the highest resolution shell; b (Otwinowski & Minor, 1997); C Rmerge = [1:h1:j 11;(h) -
(1(h) 1 ] / 1:h1:j 11;(h) I, where l;(h) and (l(h) are the ith and the mean measurements of the intensity of reflection h, 
respectively. 
The resolution cut-off for structure determination was determined by the high Rmerge values at 
higher resolutions, and by a drop in the signal-to-noise ratio below 2.0. Despite the small size 
of the crystals, the diffraction data were of a resolution suitable for co-crystal structure 
determination. The kA W and kAF datasets fall within the resolution range of other datasets 
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lis W datasets are of slightly lower resolution. The space group and unit cell dimensions for 
all four datasets are the same as those ofthe other tACE structures in the PDB. 
3.4. Co-crystal structures of kAP-derived inhibitors 
3.4.1. Structure solution, model building and refinement 
Initial phases were determined by molecular replacement using protein atoms from the 
structure of tACE-G 13 (PDB ID 2IUL) as a model. There was little change in unit cell 
dimensions of the co-crystals in comparison with the model structure, the molecular 
replacement solutions had high scores, and visual inspection of the initial electron density 
maps showed that the phases required little further refinement, indicating a conservation of 
the structure of the protein component between the liganded an unliganded structures. 
Structures of kA W and kAF in the active site of tACE-G 13 were determined to 2.18 and 2.17 
A, respectively. The progress of model building was monitored by the changes in Rcryst and 
Rjree after each cycle of model-building and refinement (Figure 3.3). Structure refinement was 
considered complete when Rjree ceased to decrease, and when any errors of stereochemistry 
introduced during the model building process had been addressed. Model refinement and 
validation statistics are presented in Table 3.3. 
--- kAW Rcryst 
--- kAW Rfree 
18·;---r-~~-T---r--'---r-~~-T---r--'---' 
o 2 3 4 5 6 7 8 
Build-refine iterations 
9 10 11 
Figure 3.3 Progress of model building and refmement for the kA W and kAF datasets, as demonstrated by 
changes in Rcrys1 and Rfree. Reryst = Lh lFo - Fel / Lh Fo, where Fo and Fe are the observed and calculated structure 
factor amplitudes of reflection h of the working set, respectively; Rfree is equal to R.,ryst for h belonging to the test 
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Table 3.3: Model refinement statistics for the co-crystal structures of kA W and kAF in the active site of tACE-
013. 
No. reflections, working set [% oftotal measured] 
No. reflections, test set [% of total measured] 
Rcryst (%) a,b 
Rfree (%) a,e 
Luzzati error (A) [test set] 
SigmaA error (A) [test set] 
R.m.s. deviations from ideality 
bonds (A) 
angles (0) 
dihedral angles (0) 
improper angles (0) 
Mean B-factor (A2) [min-max] 
aU atoms 
ligand atoms 
B-factor r.m.s. deviation (A2) 
bonded mainchain atoms 
bonded sidechain atoms 
angle mainchain atoms 
angle sidechain atoms 
Number of atoms 
solvent atoms 




% unit cell volume occupied 

















































a Values in parentheses represent the highest resolution shell: 2.18-2.26 A for kA Wand 2.17-2.25 A for kAF; 
b Rcrysl = Lh !Fo - Fel I Lh Fo. where Fo and Fe are the observed and calculated structure factor amplitudes of 
reflection h of the working set, respectively; C Rfree is equal to Rcrysl for h belonging to the test set of reflections; 
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The final R-factors are what could be expected for data of this resolution and containing 
flexible regions. The use of the same test set of reflections as was selected for solution of the 
original structure of tACE-G 13 used for molecular replacement (PDB ID 2IUL) resulted in 
the selection of test sets comprising 5.3% and 4.6% of reflections, close to the recommended 
5% (Brunger, 1992). 
The high upper limit of B-factors (individual isotropic atomic displacement parameters) for 
all atoms is the result of the inclusion of side chain atoms having ambiguous density by 
selecting a plausible conformation and allowing the B-factors to refine to high values as an 
indication of disorder. The average B-factors are thus a better indication of the quality of the 
models in this case. Atoms with very low B-factors include both protein and water atoms. 
The lowest B-factor in the kAW structure is that ofR489 O'l"lll), which is a chloride ligand 
and is thus probably stabilised by the chloride ion. The lowest B-factor in the kAF structure 
is that ofK454 O\J~), which lines the active site; there is no clear reason for the high degree of 
order for this atom. Low B-factors on water molecules (such as waters 1002 (B = 4.4), 1007 
(B = 5.23) and 1016 (B = 5.44) of the kA W structure) could indicate partial occupancy of the 
sites by chloride ions, however since the B-factors of these water molecules are comparable to 
the B-factors some protein atoms, this evidence is not conclusive. The ligand B-factors 
indicate a high degree of order for most atoms, with a few high B-factors arising from poor 
density for the P2' Phe ofkAF. 
The electron density around the N and C termini and some surface loops (103-109, 295-300, 
433-440) was weak, indicating disorder in the crystal lattice. Depending on the quality of the 
density maps, these residues were included with high B-factors or deleted, resulting in 
differing numbers of protein atoms between the four models. In particular, residues 297, 435 
and 436 could not be built in the kA W structure, while other residues in these loops have high 
B-factors. Loops 295-300 and 433-440 have been observed previously to be partially 
disordered in all of the ACE crystal structures solved to date and their location across one end 
of the active cleft may play a role in allowing the cleft to open during substrate binding 
(Watermeyer et al., 2006). Loop region 103-109 also has high B-factors and contains an N-
linked glycosylation site. Apparent disorder in this region may thus be real structural 
variation or may result from heterogeneity in glycosylation state. None of these loops 
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The backbone torsion angles of all of the residues built fell in the allowed or favoured regions 
of the Ramachandran plot, as calculated using Molprobity (Davis et al., 2004). 
Ramachandran plots are shown in Figure 3.4. 
A B 
Psi Psi 
. , eu -'f+-.,.-r+--__,,_~f"--r-,---..,.__r_,__,,_.,.,...t_rl'"T"l r-h-r...,.,---IY 
-lao Phi ,ec· -leo o Phi ,eo 
Figure 3.4 Ramachandran plots for the co-crystal structures ofkA W (A) and kAF (B) in the active site oftACE-
G 13. Favoured regions are enclosed by the light blue contours and additionally allowed regions by the dark blue 
contours. Plots were generated using Molprobity (Davis e/ aI., 2004). 
3.4.2. Structure overview 
Co-crystal structures of kA W and kAF with tACE-G 13 were solved by molecular 
replacement and refined to final crystallographic R-factors of 20.0 % in both cases (see Table 
3.3). In both the kA Wand kAF co-crystal structures, the protein component is in an identical 
confonnation to the inhibitor-free tACE-G 13 structure (PDB ID 2IUL), and to the minimally 
glycosylated wild-type tACE structure (PDB ID 1086), as evidenced by low all-atom r.m.s. 
deviations (Table 3.4). Overall, this structure is mostly alpha helical and ellipsoid in shape, 
containing two chloride ions, with the zinc ion buried deep in the active site cleft (Figure 
3.5). The lowest r.m.s. deviations in atomic positions between structures were seen in the 
zinc-binding residues and at the second chloride-binding site (CL2), which is close to the 
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Table 3.4. Root mean square deviations between co-crystal structures of tACE-G 13 with kA W (kA W) and kAF 
(kAF), unliganded tACE-G 13 (POS ID 2IUL) and minimally-glycosylated wild-type tACE bound to lisinopril 
(tACE-LPR; POS ID 1086). 
Structures aligned R.m.s. deviations (A) 
Reference Comparison overall a side b main C 
• d 
ZIDC CLl e CL2 f active site g 
kAW kAF 0.60 0.79 0.27 0.09 0.52 0.17 0.17 
kAW tACE-GI3 0.61 0.82 0.26 0.18 0.59 0.19 0.33 
kAF tACE-GI3 0.67 0.87 0.37 0.19 0.47 0.19 0.35 
kAW tACE-LPR 0.69 0.91 0.32 0.17 0.57 0.16 0.35 
kAF tACE-LPR 0.76 0.98 0.40 0.19 0.49 0.17 0.38 
tACE-GI3 tACE-LPR 0.50 0.65 0.27 0.14 0.33 0.18 0.19 
a all atoms; side chain atoms; C main chain atoms; zinc-binding residues; e residues within 5 A of chloride CLI 
(WI82, R186, 0507, P508, R489, W485, W486); f residues within 5 A of chloride CL2 (M223, Y224, P407, 
P519, Y520, 1521, R522); g residues within 6 A of kAW and kAF in the active site (N70, E143, Q281-T282, 
H353-W357, E376, V379-V380, H383-E384, H387, F391, Y394, H410-E4II, 0415, 0453-K454, F457, F460, 
K511-H513, S516, V518, Y520, R522-Y523, F527). 
Figure 3.5 Cartoon representation showing overviews of the structures of kA W (A) and kAF (S) in the active 
site of tACE-GI3. The protein backbone is shown in ribbon representation, with subdomains 1,2 and 3, as 
described in chapter I, coloured red, blue and light green, respectively. The zinc and chloride ions are shown as 
grey and green spheres, respectively, glycan residues are shown as dark blue sticks, kA W as orange sticks and 
kAF as magenta sticks. 
The inhibitors were built into clear density present in the active site in O"A-weighed Fobs-F calc 
and composite omit maps (Figure 3.6). Weak density around the P2' side chain of kAF 
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Nine residues that interact with kA W and kAF directly, or indirectly via solvent atoms, are 
substituted in the N domain and may thus contribute to their domain-selectivity (Figure 3.6). 
3.4.3. Trapping of a tetrahedral transition state in the active site 
These inhibitors have a ketone zinc-binding moiety analogous to the carbonyl oxygen of the 
scissile peptide bond, however the density maps surprisingly indicated the presence of a 
hydrated geminal diolate (gem-diol) at the active site, in which two oxygens are attached to 
the carbonyl carbon (Figures 3.6 and 3.7). 
In zinc metalloproteases, peptide bond hydrolysis is thought to occur via a tetrahedral 
transition state, which forms upon nucleophilic attack of the carbonyl carbon by an activated 
zinc-bound water molecule at the active site (Lipscomb & Strater, 1996; Pelmenschikov et ai., 
2002). This is followed by protonation of the scissile amide nitrogen and subsequent peptide 
bond cleavage. The gem-diol observed here is reminiscent of the tetrahedral transition state, 
indicating that the replacement of the scissile peptide bond nitrogen with a carbon atom in 
these inhibitors (Figure 3.1) led to the trapping of the hydrated transition state at the active 
site (Figure 3.7). 
Similar transition states have been observed previously in the structures of carboxypeptidase 
A (CPA) co-crystallised with keto methylene inhibitors 5-benzamido-2-benzyl-4-oxopentanoic 
acid (BOP) and 5-arnino-(N-t-butoxycarbonyl)-2-benzyl-4-oxo-6-phenylhexanoic acid 
(Christianson et ai., 1987; Shoham et ai., 1988; structures not available in the PDB). In these 
structures, the hydrated form of the ketone was observed at the enzyme active site despite the 
fact that this form does not occur « 1 %) in aqueous solution. Active site stabilisation of gem-
diols is commonly observed for aldehyde inhibitors (for example, PDB IDs lLAN (Strater & 
Lipscomb, 1995) and 1CBX (Mangani et ai., 1992)) and inhibitors containing activated 
electrophilic ketones (for example, PDB IDs 10D1 (Coates et ai., 2003) and INJs (Zhang et 
al.,2003)). However, the hydration of a ketone in the absence of an activating group, as seen 
here, has to the best of our knowledge only been reported in two other crystal structures, those 























Figure 3.6 Stick representation of kA W (A) and kAF (B) in the active site of tACE-G 13. The inhibitor 
molecules are shown in yellow sticks in density from the first crA-weighted Fobs-Feale difference density map 
(purple mesh) into which the inhibitor model was built, contoured at 3cr. In A, the active site-associated glycerol 
(GOL) and acetate (ACT) molecules are also shown in crA-weighted Fobs-Fcale difference density. The position of 
the active site zinc ion (ZN2) is shown as a green non-bonded sphere, indicated with an arrow, and zinc-binding 
residues are shown in black lines in the background. Inhibitor-contacting residues that differ between domains 
are shown in yellow (tACE residues from the co-crystal structure) and purple (N domain residues from the 
aligned N domain structure, PDB ID 2C6F) sticks. Residue labels are given as tACEIN domain, and the PI> Pz 















Figure 3.7 Stabilisation of the hydrated gem-diol transition state in the active site. The ketone inhibitor kA W 
(blue sticks) is shown in (JA-weighted Fobs-Feale density (purple mesh), as in Figure 3.6. The view is orientated to 
show the gem-diol moiety coordinating the active zinc ion (grey sphere). Zinc-coordinating residues and those 
involved in stabilising the intermediate are shown as yellow sticks and labeIJed. 
The gem-diol oxygens in the structures of kA W and kAF have partial negative charges and 
interact with the active site zinc ion (Table 3.5), in similar positions to the carboxyl oxygens 
of tACE-bound lisinopril and enalaprilat (PDB IDs 1086 and 1 UZE). Y523 and E384, which 
has been proposed to shuttle a proton between the attacking nucleophilic water and the 
leaving amide, also make hydrogen bonds with the gem-diol (Figure 3.7). In the structure of 
CPA bound to BOP the gem-diol has longer zinc-coordinating distances (2.51 and 2.91 A; 
Christianson et al., 1987) than those observed here, however it is clear from the overlap of the 
gem-diol oxygens of kA W and kAF with the zinc-binding oxygens of the other inhibitors that 
these positions are characteristic of the ACE active site. 
Thus, the visualisation of the gem-diol in the present structures demonstrates that in the 
absence of a leaving amide nitrogen, the catalytic residues of ACE are able to stabilise the 
tetrahedral transition state. This stabilisation probably plays a transient role in overcoming 
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3.4.4. Active site interactions ofkA Wand kAF 
kA W and kAF take on a similar confonnation in the active site to that seen in previous 
inhibitor co-crystal structures. The P2' Trp and PI Phe align closely with the equivalent 
groups of the C-domain-selective inhibitor RXP A380 in the active site of tACE, although the 
backbone of RXP A3 80 is constrained to a different path around the PI' Pro moiety (Figure 
3.8). Docking studies of kAP predicted similar binding sites to those observed here for the PI 




Figure 3.8 Alignment of the co-crystal structures of tACE with kA W (yellow sticks), kAF (green sticks) and 
RXPA380 (PDB ID 20C2; orange sticks) in the active site. Structures were aligned by pair-wise alignment of 
the alpha carbons of the zinc-binding residues. The zinc ion is shown as a grey sphere, and adjacent protein 
components of all three structures are shown in lines of the same colour as the inhibitors to indicate the degree of 
alignment. 
There is very little variation in the active site oftACE in any of the crystal structures solved to 
date. Notable exceptions are adjacent residues D453 and S284, which appear to be flexible, 
taking on different confonnations in the minimally glycosylated wild-type tACE structures 
from the tACE-G 13 structures, and Q281, which appears to swivel slightly about XI and XJ to 
make room for the bulky Trp moiety of kA W. The details of the polar contacts and non-polar 
proximities involved in inhibitor binding are presented in Tables 3.5 and 3.6, respectively. 
kA W makes nine polar contacts (potential hydrogen bonds and ionic interactions) with seven 
protein side chains, while kAF makes nine polar contacts with six protein side chains (Table 
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and to negligible changes in E384 which nonetheless affect hydrogen-bond detection. 
Additional hydrogen bonds are made with four water molecules, whose positions are 
conserved between the structures, as well as with a glycerol molecule derived from the cryo-
protectant in the kA W structure. These solvent molecules form part of a hydrogen bonding 
network connecting the inhibitor to other active site residues and to the bulk solvent (Figure 
3.9). 





Inhibitor Interacting residue, N domain Distance (A) b 
atom • atom • equivalent kAW kAF 
OXT LYS 511, N<; LYS 489 2.73 2.76 
OXT GLN281, NE2 GLN 259 (3.76) 2.89 
OXT TYR520,OH TYR498 2.63 2.76 
OXT HOH 1006,0 (1009) (3.47) 3.20 
0 HOH 1006, 0 (1009) 2.79 2.78 
o HOH1186,0(1175) 2.67 2.59 
NEl GOL 704, 02 2.79 
CE3 (CEI) HOH 1162, 0 (1199) 2.93 2.95 
N HOH 1162,0 (1199) 3.18 3.22 
OAA HIS 513, NE2 HIS 491 2.78 2.84 
OAA HIS 353, NE2 HIS 331 2.80 2.66 
OAE ZN2 ZN2 2.23 2.07 
OAE TYR 523, OH TYR 501 2.34 2.41 
OAE HOH 1165, 0 (1081) 3.38 3.32 
OAF ZN2 ZN2 2.42 2.52 
OAF GLU 384, OE2 GLU 362 2.58 2.80 
OAF GLU 384, Od GLU 362 3.08 3.11 
NBA HOH 1165, 0 (l081) 3.10 3.08 
OAC ALA 356, N ALA 334 2.73 2.83 
OAC GLU 384, OEI GLU 362 3.32 (3.53) 
Polar and nonpolar 
contacts via solvent atom 
W279, Q281, K511, GOL, 
water 
W279, Q281, K511, GOL, 
water 
V3S0, GOL, water 
N277, Q281, T282 
V3S0, H3S3, water 
V3S0, H3S3, water 
E411, V5IS, R522, Y523 
E411, V5IS, R522, Y523 
a kAF atom names and water numbers are given in parentheses where these differ from those ofkA W. 
b Values in parentheses are greater than the maximum hydrogen-bonding distance (3.4 A). 
The active site glycerol molecule in the kA W structure is highly ordered and was clearly 
present in O'A-weighted Fobs-Fcalc and composite omit maps calculated early in the refinement 
process (Figures 3.6 (A) and 3.9 (A». It is linked via several hydrogen bonds to the water 
network in the S2' pocket, and to polar and charged residues T282, Q281, N277 and E376 
(Figure 3.9 (A». The conformation of the Trp moiety ofkA W does not appear to be affected 
by the glycerol however, since it takes the same conformation as the P2' Trp of RXPA380 
(PDB ID 20C2; Corradi et al., 2007), which does not have a glycerol at this position. 
Moreover, no glycerol-like density was present at this position in O'A-weighted Fobs-Fcalc and 
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Figure 3.9 Close-up of the ~' pocket with kA W (A) and kAF (B), showing the water network and glycerol 
molecule. Glycerol and inhibitors are shown as yellow sticks, water oxygens and the active site zinc ion as blue 
and green nonbonded spheres, respectively, and water hydrogen bonds as blue dashed lines. Protein residues are 
shown in line representation. As in Figures 3.6 and 3.7, the inhibitors and glycerol are shown in the ftrst O'A-
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A 
B . '- " 
Figure 3.10 Evidence for the presence of glycerol in the active site of tACE-GI3 with kAW, versus the data 
from the structure of tACE with RXP A380 (PDB lD 20C2). (A) The Pz' Trp of kA W and associated glycerol 
molecule (yellow sticks) in the active site of tACE-G 13, in density (blue mesh) calculated using the (<JA-
weighted) composite omit map protocol of eNS (Brtinger et aI., 1998) with simulated annealing, and contoured 
at 1.0 <J. (B) No glycerol-like density was observed in an annealed <JA-weighted composite omit map (blue 
mesh) calculated using the RXPA380 structure (pink sticks) with a glycerol (yellow lines) added in at the same 
position, and refIned against the deposited structure factors. 
Close proximities between nonpolar atoms are also observed between the inhibitors and 17 
active site residues as well as a number of water molecules (11 and 13 for kA W and kAF, 
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Table 3.6 Nonpolar contacts and close proximities of kA W and kAF, including hydrophobic contacts, 
unfavourable contacts and waters. 
Inhibitor Inhibitor Adjacent residue, N domain Distance (A) Polar and nonpolar 
Moiety Atom • atom • equivalent kAW kAF contacts via solvent 
atom 
P2' CA* TYR523, Ce2 TYR501 3.61 3.54 
CB TYR523, C82 TYR501 3.52 3.43 
CB PHE457, CZ PHE435 3.65 3.68 
CDI (CD2) GLN 281, Ne2 GLN 259 3.52 3.74 
CDI (CD2) PHE457,Cd PHE435 3.78 4.61 
NEl (CE2) THR282, Cy2 SER260 4.10 4.94 
(CE2) >I< HOH 1096,0 3.39 Q281, T282, water 
(CE2) HOH 1083,0 3.56 E376, V380, water 
CZ2 GOL 704, C3 3.82 V380 
CZ2 (CZ) HOH 1161,0 (1105) 3.72 3.93 E376, V379, D453, GOL, 
water 
CH2 (CZ) VAL 379, Cyl SER357 4.05 5.17 
CH2 (CZ) VAL 380, Cy2 THR358 4.87 4.99' 
CH2>1< HOH 1191, 0 3.20 K454, F527 
Cz3 (CE1)'" HIS 383, N81 HIS 361 3.65 4.20 
Cz3 (CE1) ASP 415, 081 ASP 393 3.64 4.23 
Cz3 (CEl) ASP 415, 082 ASP 393 3.47 3.92 
Cz3 (CDI) PHE 527, Cd PHE 505 4.04 4.11 
CE3 (CDl) HOH 1016,0 (1008) 4.05 3.86 E411, D415, S526 
CE3(CDI) HOH 1162,0 (1199) 2.93 3.05 V380, H383, water 
N TYR523, CE2 TYR501 3.60 3.37 
PI' CAY HOH 1162,0 (1199) 3.34 3.41 V380, H383, water 
CAW HIS 353, NE2 HIS 331 3.61 3.77 
CAW ALA 354, 0 ALA 332 2.92 3.00 
PI CBL ALA 354, 0 ALA 332 3.56 3.67 
CBL SER355, Ca. SER 333 4.11 4.18 
CAO'" PHE 512, CE2 PHE490 3.63 3.68 
CAO SER355, C~ SER333 3.79 3.83 
CAO'" HOH 1020, 0 (1056) 3.57 3.88 H353, S355, K368, F512, 
water 
CAT SER 516, C~ ASN 494 5.70 5.69 
CAT HOH 1169, 0 (1077) 3.53 3.66 N70, V351, F512, water 
CAG ACT 706, C 3.91 N66, W357, water 
CAl >I< VAL 518, Cy2 THR496 3.59 3.35 
CAP'" HOH 1165, 0 {1081} 3.66 3.68 E411, V518, R522, Y523 
P2 CBE HIS 387, NE2 HIS 365 3.59 3.55 
CAR GLU 411, OE2 GLE 389 3.46 3.54 
CAR'" HIS 387, Cel HIS 365 3.50 3.77 
CAR HOH 1165,0 (1081) 3.21 3.20 E411, R522, Y523 
CAL HOH 1058,0 (1090) 3.48 3.44 P407, H410, E411, R522, 
water 
CAL HOH 1163,0 (1086) 3.68 3.64 P407, water 
CAR'" HIS 410, CO2 HIS 388 3.98 3.80 
CAR HOH 1228, 0 3.48 E403, water 
CAK* PHE 391, C~ TYR369 3.35 3.45 
CAK HOH 1232, 0 (1229) 3.82 3.98 Y360, water 
CAQ ALA 356, 0 ALA 334 3.32 3.50 
a kAF atom names and numbers are given in parentheses when these differ from those ofkA W ... More than one 
close proximity between the side chain moieties concerned (e.g. aromatic ring stacking); shortest interatomic 
distance quoted. 
Some of these residues (T282, S355, V379, V380, H387, F457, F512, V518 and F527) could 
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H353, A354, E384, D415 and the water molecules) are polar or charged groups, and some 
(H383 and Y523) make both favourable and unfavourable contacts. 
3.5. Determinants of domain-selectivity from ketone inhibitor interactions 
3.5.1. kAP, kA Wand kAF as tools for identifYing determinants of domain-selectivity 
The ketone zinc-binding moiety of kAP and its derivative inhibitors has lower affinity for the 
active site zinc ion than the carboxyl, sulphydryl and phosphinyl groups of other previously-
studied inhibitors (reviewed by Redelinghuys et al. (2005)). This results in a situation similar 
to the binding of a natural substrate, with the affinity of the inhibitor depending to a great 
extent on the contributions of other groups. These inhibitors are thus suitable tools for 
investigating the contributions of moieties other than the zinc ion to inhibitor binding. 
The chemical structures of kA W and kAF are very similar to their parent molecule, kAP, 
differing only at the P2' position (Figure 3.1), however they show markedly lower affinity for 
the N domain, leading to enhanced C-domain-selectivity (Table 3.7). The dramatic reduction 
in affinity for the N domain can be explained by their modes of interaction with the active 
site, summarised in Tables 3.5 and 3.6. The following discussion uses the numbering of 
tACE when referring to the C domain. tACE residue numbers can be converted to C domain 
numbering by adding 576. 
Table 3.7 Domain-selectivity of novel inhibitors kA Wand kAF, in comparison with their parent molecule kAP 
(Watermeyer et aI., Appendix D). 
Inhibitor KiC domain (IlM) a K."N domain (1lM) a C-selectivity (K,N domain I K iC domain) 
kAP 0.05 1.5 30 
kAW 0.68 854.2 1256 
kAF 0.83 > 500 b > 600 
a Ki data were determined using the fluorogenic peptide substrate Abz-FRK(Dnp)P-OH. b No inhibition detected 
up to a concentration of 500 iJ.M. 
3.5.2. Selectivity ofthe parent molecule kAP - the Sl and S2 pockets 
kAP has 30-fold higher affinity for the C domain than for the N domain (Table 3.7). This 
domain-selectivity does not reside in the P2' Pro moiety, since it has been shown that Pro at 
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from the co-crystal structures of tACE and the N domain with lisinopril (PDB IDs 1086 and 
2C6N, respectively), one can see that a P2' Pro stacks against Y523 and its N domain 
equivalent, Y501, making no interactions with residues that differ between domains. The 
selectivity ofkAP must thus be attributed to its PI and P2 moieties, which are retained in kA W 
andkAF. 
The Sl and S2 pockets of the N and C domains differ in four residues that lie within 6 A of 
kA W and kAF, of which S516, V518 (Sl pocket) and F391 (S2 pocket) make hydrophobic 
contact with the inhibitor PI and P2 side chains. These are replaced by the charged and polar 
residues N494, T496 and Y369, respectively, in the N domain (Figure 3.6; Tables 3.5 and 
3.6). 
The substitution of F391 with Tyr in the N domain introduces a hydroxyl group into the S2 
pocket, which would result in steric hindrance of the binding of the P2 benzoyl moiety of kAP 
(Figure 3.6). The importance of this residue for selectivity has been confirmed by mutation of 
F391 to Tyr in the C domain context, which resulted in an 8.6-fold reduction in affinity for 
kAP (Watermeyer et ai., Appendix D). This substitution has also been identified as 
contributing to the C-domain-selectivity of the phosphinic peptide inhibitor RXPA380, which 
also has a benzyl group at this position (Corradi et al., 2007) and may explain the observation 
that a P2 Ser residue, which in contrast to a benzyl group is small and polar, confers N-
domain-selectivity (Michaud et ai., 1999). 
Also in the S2 pocket, E403 of the C domain is replaced by R381 in the N domain, which is 
4.6 A from the P2 benzoyl ring when the structure of the N domain (PDB ID 2C6F) is aligned 
with the co-crystal structure ofkA W (Figure 3.6). The bulky, positively charged side chain of 
R381 would thus approach the P2 moiety, replacing the smaller, negatively charged E403, 
which does not interact with the inhibitor (Figure 3.6). This could account for the observation 
that a positively-charged P2 Lys is unfavourable for N domain binding (Cotton et al., 2002), 
however no effect on kA W affinity was observed upon mutation of E403 to Arg in the C 
domain (Watermeyer et ai., Appendix D), suggesting that this residue is not important for the 
binding of compounds with a P2 benzyl ring. 
In the Sl pocket, the substitution of S516 with N494 in the N domain replaces a small polar 
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a hydroxyl moiety in close proximity to the P1 Phe ring of kA Wand kAF (Figure 3.6). N494 
of the N domain is a potential N-glycosylation sequon, although no glycan was observed at 
this site in the N domain crystal structure. The presence of Ser instead on Asn at this position 
in the N domain of rat ACE has been suggested to account for its C domain-like selectivity 
(Jullien et at., 2006). 
V518 has been confIrmed by mutagenesis to be important for the C-domain-selectivity of 
kAP, with replacement of V 518 with Thr resulting in a low affinity for kAP similar to that of 
the N domain, while mutation of S516 had little effect (Watelmeyer et at., Appendix D). The 
effect of the V 518T substitution is not steric, however the association of the P 1 Phe side chain 
with T 496 of the N domain is probably made unfavourable by the displacement of any water 
molecules hydrogen-bonded to the hydroxyl moiety, which would be necessary for binding of 
the bulky phenyl group. Displacement of waters around V518, in contrast, would result in a 
favourable increase in entropy. No waters are present at this site in the N domain crystal 
structures (PDB IDs 2C6N and 2C6F), however few water molecules were added to these 
structures due to the low resolution of the data (Corradi et at., 2006). This S1 subsite 
alteration may explain the moderate C-domain-selectivity of lisinopril and enalaprilat, whose 
PI benzyl groups overlap with the Phe ring of the present structures, as well as the observation 
that a bulky PI moiety confers C-domain-selectivity (Acharya et al., 2003). 
The C-domain-selectivity of kAP is thus due to sterically and entropically favourable 
hydrophobic interactions between the bulky hydrophobic PI and P2 benzyl moieties and F391 
and V 518, which are replaced with polar groups in the N domain. Mutation of these residues 
to their N domain counterparts further confIrmed that these substitutions contribute to the 
selectivity of kA Wand kAF, which differ from kAP only in the P2' position (Watermeyer et 
at., Appendix D). 
3.5.3. kA W selectivity in the S2' pocket 
The single residue replacement of Trp for the P2' Pro of kAP reduces the affinity of kA W for 
the N domain dramatically, making it approximately 40-fold more C-domain-selective than 
kAP. This effect is the net result of a 570-fold decrease in affinity for the N domain, together 
with a 13-fold decrease in affinity for the C domain, relative to kAP (Table 3.7). The loss in 
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hydrophobic stacking interactions of the Pro moiety of kAP, however the greater loss of 
affInity for the N domain can be attributed to interactions in the S2' pocket, described below. 
In the crystal structure, the P2' Trp indole nitrogen of kA W makes a hydrogen bond to a 
highly ordered glycerol molecule, which is linked via numerous hydrogen bonds to the water 
network and to polar and charged residues T282, Q281, N277 and E376 (Figures 3.6 (A) and 
3.9 (A)). Since this glycerol is derived from the cryo-protectant used during data collection, 
crystal growth must have occurred in its absence, suggesting that a water molecule was the 
original acceptor for the Trp H-bond. In addition, the Trp interacts closely with a 
hydrophobic patch created by T282, F457, F527 and Y523 on one side, and with H383, V379, 
V380 and a water molecule on the other side. Four of these ten residues, T282, E376, V379 
and V380, are substituted in the N domain (Figure 3.6 (A); Table 3.6). 
The substitution of S284 and D453, located deep in the S2' pocket in the C domain, with the 
bulkier charged residues E262 and E431 in the N domain, may also contribute to C-domain-
selectivity. The side chains of S284 and D453 have been built in different conformations in 
tACE crystal structures, and appear to be able to swing away from the active site to allow for 
the binding of bulkier side chains (see for comparison PDB IDs 1086 and 2IUL). This 
mobility may not be possible for their bulkier N domain equivalents. Interestingly, the N 
domains of rat and mouse ACE have substrate selectivity similar to that of the human C 
domain, thought to result from the presence of human ACE C domain-like sequence at 494, 
453 and 357 (Jullien et al., 2006). 
All these substitutions together amount to an N domain S2' pocket that is considerably more 
polar and constrained in nature than the C domain pocket, and hence less conducive to the 
binding of bulky hydrophobic residues such as Trp. This property of the S2' subsite has been 
predicted from the moderate C-selectivity of known inhibitors trandolaprilat, quinaprilat and 
perindoprilat, which also have bicyclic P2' moieties (Perich et a!., 1994; Acharya et al., 2003). 
Mutagenesis studies have confirmed the importance of some of these substitutions for the C-
domain-selectivity of kA W, with mutation of E376 and V380 to their N domain equivalents 
resulting in 3.4- and 3.9-fold decreases in affInity for kA W (Watermeyer et al., Appendix D). 
Similar mutation of T282 had no effect on affinity and mutation of V379 caused an increase 
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more polar T358 in the N domain removes the entropic contribution of this hydrophobic 
interaction to kA W binding, similar to the V518T substitution in the SI pocket. Since E376 
interacts with the Trp indole N indirectly via the glycerol (or water network), the effect of the 
E376D substitution is probably a result of the weakening of this interaction due to the 
lengthening of the distance between the negatively charged group and the indole nitrogen. In 
the N domain structure (PDB ID 2C6F), this side chain is turned away from the active site. 
The increase in affinity for kA W observed when V379 is mutated to Ser is not readily 
explained by the crystal structure but may be due to a rearrangement of side chains in the S2 
pocket, possibly leading to the formation of a water-mediated hydrogen bond between the Ser 
and the Trp indole N. This is supported by the observation that this mutant did not have 
increased affinity for kAF, which lacks a P2' hydrogen-bonding moiety (Watermeyer et ai., 
Appendix D). 
The overall low affinity of the N domain for kA W is thus probably due to the combined effect 
of the S2' substitutions E376D and V380T, possibly with a contribution from the S284E and 
D453E substitutions, together with the Sl and S2 pocket substitutions described above. 
3.5.4. kAF selectivity in the S/ pocket 
Like the Trp of kA W, the P2' sidechain of kAF is in close proximity to V379 and V380, as 
well as the conserved hydrophobic residues H383, Y523, F527 and F457, but many of these 
residues are more distant than in the case of kA W because of the smaller size of the Phe side 
chain (Table 3.6). Moreover, the aromatic ring is unable to make a hydrogen bond to the 
water network, and in place of the glycerol moiety seen in the kA W structure, a ring of 
ordered waters is present, interacting with the polar residues beyond (Figure 3.9 (B)). The 
effect of the smaller size of this side chain, together with the lack of a hydrogen-bonding 
moiety, is evident in the poorly-defined density and higher atomic displacement parameters of 
this group in the crystal structure, which indicate a degree of disorder (Figures 3.6 (B) and 3.9 
(B)). 
kAF has similar affinity for the C domain to kA W, and exhibits no inhibition of the N domain 
at up to 500llM inhibitor, implying a Ki considerably greater than 500 11M, similar to what 
was observed for kA W (Table 3.7). Mutagenesis studies confirmed that the same P2' 










CHAPTER 3: Results and Discussion 58 
the smaller size and disorder of the Phe group (Watermeyer et al., Appendix D). From this 
investigation then, it can be concluded that the C-domain-selectivity of the kAP P2' 
derivatives kA W and kAF results from interactions between their bulky hydrophobic side 
chain moieties and the C domain-specific residues F391 (S2), V518 (S1)' E376 (S2') and V380 
(S2'). Interactions with their N domain equivalents are less favourable. 
3.6. Co-crystal structures oftACE-G13 with a lisinopril-derivative inhibitor 
3.6.1. Structure solution, model building and refinement 
Two enantiomers oflisW were derived from lisinopril by P2' substitution (Figure 3.1), one of 
which, lisW-S, was shown to be strongly C-domain-selective (Redelinghuys et al., 2006). X-
ray diffraction datasets were collected for crystals grown from solutions containing both 
enantiomers of lisW (see Table 3.2), and phases were determined by molecular replacement 
using protein atoms from the structure oftACE-G13 (PDB ID 2IUL) as a model. As was the 
case for the kA W and kAP datasets, the molecular replacement solutions had high scores and 
yielded initial phases that required little further refinement. 
During the model building process, it became clear that both datasets contained the same 
enantiomer, lisW-S, in the active site. Attempts to build the R enantiomer into the active site 
produced negative difference density near the chiral carbon, and failed to position the Pi Phe 
side chain properly in the density (Figure 3.11). This suggests that the purified lisW-R used 
for co-crystallisation contained traces of lis W -S, which were selected by the tACE active site. 
Models containing the S enantiomer were thus built for both datasets, to 2.3 and 2.4 A, and 
refilled to final crystallographic R-factors of 21.6% and 22.6% (Table 3.8). The models are 
referred to as lisW-A and lisW-B, according to the dataset used. 
As was the case for the kA Wand kAP structures, the R-factors are good for structures of this 
resolution that contain flexible regions. The method used for test set selection was the same 
as for the ketone inhibitor structures, so that the reflections used were the same set that were 
used for the molecular replacement model, amounting to 4.4% of reflections for both datasets. 
The B-factors for the ligand in the lisW-A model were higher than those in the lisW-B model, 
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ligand density in the active site, which was better for the lisW-B dataset. The lisW-B dataset 
is of slightly higher resolution (2.30 A) than the lisW-A dataset (2.40 A), however the 
redundancy in the outer shell of the lisW-B dataset is slightly lower than that of the lisW-A 
dataset (Table 3.2), which suggests that resolution is not the reason for the difference in 
quality of the maps in the active site. The poor quality of the ligand density is thus likely due 
to lower occupancy of the ligand in the lisW-A dataset, so that the lisW-B model should be 
regarded as more reliable than the lisW-A model. 
H 









Figure 3.11 Left panel: The lisW-R enantiomer (green sticks) is shown in O'A-weighted 2Fobs-Fca/c (purple mesh, 
contoured at 1.00') and negative Fobs-Fca/c density (red mesh, contoured at -3.00'), calculated after attempting to 
build tills enantiomer into the active site using the lisW-B dataset. lisW-S is shown in black lines for 
comparison, and the chiral centre is indicated with an asterisk. The active zinc ion (grey sphere) and zinc-
binding residues (green lines) are also shown in O'A-weighted 2Fobs-Fca/c density, Right panel: The arrangement 
of groups about the indicated chiral centre for the Sand R enantiomers. R' = the remainder of the molecule (P " 
and P2' groups). 
The progress of model building was monitored by the changes in Rcrys' and Rjree after each 
cycle (Figure 3.12). Increases in R-factors towards the end of the process are the result of the 
deletion of disordered surface loop residues, which had produced a misleading lowering of 
Rjree, as well as the re-refinement of individual B-factors. Structure refinement was 
considered complete when Rjree ceased to decrease, and when any errors of stereochemistry 
introduced during the model building process had been addressed. Ramachandran plots for 
the lisW-A and lisW-B models are shown in Figure 3.13, where it can be seen that all of the 
residues built fell within the allowed and favoured regions Table 3.8). 
Table 3.8: Refinement statistics for two models of lisW -S in the active site of tACE-G 13, built using datasets 
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No. reflections, working set [%] 
No. reflections, test set [%] 
Rc,yst (%) a,b 
R free (%) a,e 
Luzzati error (A) [test set] 
SigmaA error (A) [test set] 




improper angles (0) 
Mean B-factor (A2) [min-max] 
all atoms 
ligand atoms 
B-factor r.m.s. deviation CA2) 
bonded mainchain atoms 
bonded sidechain atoms 
angle mainchain atoms 
angle sidechain atoms 
Number of atoms 
solvent atoms 



















































Ramachandran plot, % residues in favoured regions 97.56 98.40 
60 
a Values in parentheses represent the highest resolution shell: 2.40-2.49 A for lisW-A and 2.30-2.38 A for lisW-
B; b RcryS! ::: Lh lFo - Fell Lh Fo. where Fo and Fe are the observed and calculated structure factor amplitudes of 
reflection h of the working set, respectively; e Rfree is equal to R erys! for h belonging to the test set of reflections; d 
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--*- lisW -A Rcryst 
_lisW-A Rfree 
---k- lisW -B Rcryst 
---.-lisW-B Rfree 
7 8 9 10 11 
Build-refine iterations 
61 
Figure 3.12 Progress of model building and refinement for the IisW-A and IisW-B datasets, as indicated by Rcrysl 
and RfTee . ~rysl = Lh lFo - Fel / Lh Fo, where Fo and Fe are the observed and calculated structure factor 
amplitudes of reflection h of the working set, respectively; Rfree is equal to ~rysl for h belonging to the test set of 
reflections. 
A B 
·180 a Phi 180 ·Ieo o Phi lBO 
Figure 3.13 Ramachandran plots for the co-crystal structures of lisW-A (A) and lisW-B (B) in the active site of 
tACE-G13. Favoured regions are enclosed by the light blue contours and additionally allowed regions by the 
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3.6.2. Structure overview 
As was the case for the ketone inhibitors, the protein component is in an identical 
conformation to the unliganded structure (PDB ID 2IUL), and there is very little variation 
between the two structures (Table 3.9). Fewer glycan and protein residues were built than for 
the higher resolution kA W and kAF structures, however the zinc and chloride ions were 
clearly visible (Table 3.8; Figure 3.14). 
Table 3.9. Root mean square deviations in A between the two co-crystal structures of tACE-G 13 with lisW (A 
and B), unliganded tACE-G 13 (PDB In 2IUL) and minimally glycosylated wild-type tACE bound to lisinopril 
(tACE-LPR; PDB ill 1086). 
Structure I Structure 2 overall" sideb maine zincd CLle CL2f active siteg 
A B 0.52 0.69 0.21 O.lS 0.53 O.IS 0.23 
A tACE-GI3 0.48 0.6S 0.19 0.04 0.48 0.12 O.1S 
B tACE-G13 0.36 0.49 0.13 0.14 0.29 0.10 0.16 
A tACE-LPR 0.62 0.83 0.27 0.12 0.56 0.15 0.22 
B tACE-LPR 0.56 0.74 0.25 0.13 0.33 0.16 0.17 
tACE-G13 tACE-LPR 0.54 0.70 0.27 0.14 0040 0.18 0.22 
"all atoms; bside chain atoms; cmain chain atoms; a zinc-binding residues; eresidues within 5 A ofCLl (WI82, 
R186, D507, P508, R489, W48S, W486); f residues within 5 A of CL2 (M223, Y224, P407, P519, YS20, 1521, 
R522); g residues within 6 A oflisW-8 in the active site (N70, E143, E162, Q281, H353-A3S6, Q369, E376-
D377, V379-V380, H383-E384, H387, E411, D415, K454, F457, F460, K5ll-HS13, 8S16, V518, Y520, R522-
Y523, 8526-F527, Q530) 
The r.m.s. deviation between the ligand atoms in the two structures, calculated in the context 
of an all-atom alignment, is 0.55 A. The r.m.s. deviation calculated using ligand atoms along 
is 0.46 A. Deviation between the ligand structures is probably largely due to the poor quality 
of the density for the ligand in the lisW-A dataset (Figure 3.15 (A)), also evident in high 
ligand B-factors (Table 3.8). These data may be indicative of partial occupancy of the ligand 
in this dataset, however the resolution limit of the data did not allow refinement of 
occupancies. Due to the high B-factors of the ligand in the lisW-A model, the lisW-B model 
will be used to draw conclusions about lis W -S binding. 
As was seen in the ketone inhibitor structures, and indeed in all ACE structures solved to date 
(Watermeyer et aI., 2006), surface loops 102-112, 296-299 and 434-439 showed a degree of 
structural disorder, and residues 436-438 were omitted from the lisW-S model. High B-
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Figure 3.14 Cartoon representation showing an overview of the structure of lisW-S in the active site of tACE-
G13, determined from the lisW-B dataset. The protein backbone is shown in ribbon representation, with 
subdomains 1,2 and 3, as described in chapter I, coloured red, blue and light green, respectively. The zinc and 
chloride ions are shown as grey and green spheres, respectively, glycan residues are shown as dark blue sticks, 
and lisW-S as orange sticks. 
3.6.3. Variation in the orientation of the P/ Trp between inhibitors 
Interestingly, the P2' Trp of lisW-S takes a different conformation to that observed in kA W 
and RXPA380, being flipped by approximately 70° and 1800 about Xl and 'X2 respectively, 
relative to kA W (Figure 3.16). Despite the relatively low resolution of the lisW -B dataset, the 
change in orientation was demonstrated unambiguously by the electron density (Figure 3.15 
(B)). In this orientation the Trp ring makes a new hydrogen bond with D415 (Figures 3.15 
and 3.16). 
This conformation is probably favoured in lisW-S due to hydrophobic contacts between the 
P2' Trp ring, the PI' Lys sidechain and V380, which is sandwiched between the two (Figure 
3.17). kA Wand RXPA380 lack a PI' Lys, so that the conformation observed here is probably 
less stable in these structures. The potential for a P2' Trp moiety to take two different 
conformations highlights the large volume of the S2' pocket, which allows this side chain to 


















Figure 3.15 Stick representation of the active sites of models lisW-A (A) and lisW-8 (8), showing IisW-S in 
the first erA-weighted Fobs-Feale difference density map (purple mesh) into wruch the inhibitor model was built, 
contoured at 20". The active site zinc ion (ZN2) is shown as a green non-bonded sphere, and zinc-binding 
residues are shown in black lines in the background. Inhibitor-contacting residues that differ between domains 
are shown in yellow (tACE residues from the co-crystal structure) and purple (N domain residues from the 
aligned N domain structure, PD8 lD 2C6F) sticks. D415, which forms a hydrogen bond with the P/ Trp ring N, 
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Figure 3.16 Alignment of lisW-S (IisW-B dataset; green sticks) with kAW (purple sticks) in the active site, 
showing differences in the orientation of the P2' Trp moiety. The structures were aligned by pair-wise alignment 
of the alpha carbons of the zinc-binding residues. The P2' Trp of lisW-S is rotated about Xl (yellow arrow) and X2 
(orange arrow), relative to kA W. D415 is shown in green stick representation, and the hydrogen bond with the 
lisW-S Trp ring is marked as an orange dotted line. The active zinc ion is shown as a grey sphere, and the 
surrounding residues are shown in green line representation. 
Figure 3.17 Hydrophobic stabilisation of a new conformation of the P2' Trp of lisW-S (light blue sticks and 
transparent spheres) in the active site of tACE-G 13 (IisW-B dataset, light blue cartoon representation). The side 
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3.6.4. Active site interactions oflisW-S 
lisW-S makes 11 polar contacts (potential hydrogen bonds and ionic interactions) with 11 
protein side chains (Table 3.10). In comparison with kA W and kAF, four additional contacts 
are contributed by the PJ' Lys side chain, while PI and P2 polar contacts are absent, due to the 
absence of a polar moiety in the PJ position, and to the lack of a P2 sidechain. Hydrogen 
bonds are also made with four water molecules, two of which are conserved in the kA W and 
kAF structures, and two of which are specific to this inhibitor. One of the lis W -S-specific 
waters is hydrogen-bonded to the PJ' Lys amine, and the other occupies the position of the P2 
carbonyl oxygen of kA W and kAF. The remaining two conserved waters in the kA W and 
kAF structures are excluded from this structure by the hydrophobic contact between the PI' 
Trp and P2' Lys side chains. No glycerol or acetate molecules were observed in the active 
site. 
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Distance (A) a Polar and nonpolar 
--____ ~ interactions via solvent 




3.19 (3.58) W279, Q281, K511, water 










3.19 3.39 E411, V51S, R522 
2.38 2.61 
2.81 2.70 
3.11 2.82 A356, S355, water 
a Values in parentheses are greater than the maximum hydrogen-bonding distance (3.4 A). b Distances between 
equivalent atoms in the structure oftACE with lisinopril (PDB lD 1086). 
Most of these polar interactions are conserved in the structure of tACE with lisinopril (PDB 
ID 1086), which binds in a nearly identical conformation to lisW-S (Figure 3.18). There are 
some differences in the orientation of the amine group of the PI' Lys moiety, which might be 
due to the influence of the P2' Trp moiety, and in the zinc-co-ordination distances, however 
these could equally be attributed to the lower resolution of the lis W -B dataset in comparison 
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Figure 3.18 Alignment of the co-crystal structures of tACE witb lisW-S (yellow sticks) and parent molecule 
lisinopril (PDB ID 1086; orange sticks) in the active site. Structures were aligned by pair-wise alignment of the 
aJpba carbons of the zinc-binding residues. The zinc ioo is shown as a grey spbere, and adjacent protein 
compooeots of both structures are shown in lines of the same colour as tbe inhibitor to indicate the degree of 
alignment. 
Close proximities are observed between the nonpolar atoms of lisW-S and 14 protein side 
chains (Table 3.11). Most of these contacts (H353, A354, S355, V379, V380, H383, F457, 
F512, S516, V518, Y523, F527) are probably entropically favourable, although there are 
some close contacts with charged moieties (H383, D415 and EI43). In addition to these, nine 
water molecules are in close proximity to nonpolar inhibitor moieties in the S 1 and S2' 
pockets. Contacts in the Sl' and Sl pockets are conserved in the structure of tACE with 
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Table 3.11 Distances between nonpolar atoms of lisW-S (lisW-B dataset) and other atoms in close proximity, 
including hydrophobic contacts, unfavourable contacts and waters. Equivalent distances in the co-crystal 
structure oftACE with lisinopril (PDB ID 1086) are given for comparison. 
Inhibitor Inhibitor Adjacent N domain Distance (A) Polar and nonpolar 
Moiety Atom residue, equivalent 
LPR 8 
interactions via solvent 
atom lisW-S atom 
Pz' CA* TYR523, CE2 TYR501 3.76 3.74 
CB * PHE457, C~ PHE435 3.72 3.72 
CD1* PRE 527, CEl PHE 505 3.64 
CDI TYR523, C82 TYR501 3.57 
NEl* HIS 383, N81 HIS 361 3.45 
CZ2 ASP 415, 081 ASP 393 3.86 
CH2* VAL 379, Cyl SER357 4.11 
CH2 GLU 376, 0 ASP 354 5.21 
CZ3* VAL 380, Cy2 THR358 3.36 
CH2* HOH 1079, 0 3.82 E376, V379, water 
CZ3 HOH 1043, 0 3.93 E376, water 
CE3* lisW, CAU 4.33 
CE3 HOH 1121, 0 3.93 Q281, T282, water 
N TYR523,0,2 TYR501 3.74 3.81 
PI' CAY HIS 383, C82 HIS 361 4.30 4.21 
CAU* lisW, CE3 4.33 
CAS'" ALA 354, C~ ALA 332 4.04 4.23 
CAS* HIS 353, NE2 HIS 331 3.41 3.55 
CAR* VAL 380, Cyl THR358 3.41 3.99 
CAQ HOH 1034,0 4.44 3.91 L161, E162, T166, W279, water 
CAQ HOH 1177,0 4.48 3.97 lisW 0, K511, W279, Q281, 
water 
PI CBL ALA 354, 0 ALA 332 3.20 3.43 
CBL HIS 353, C82 HIS 331 3.65 3.94 
CBL HOH 1109,0 3.75 3.69 A356, E384, lisW OAF, water 
CAX* VAL 518, Cyl THR496 4.10 4.09 
CAX HOH 1041,0 3.50 3.66 E411, V518, R522, Y523 
CAP HOH 1174, 0 4.09 4.53 A356, H387, F391, water 
CAJ* VAL 518, Cy2 THR496 3.89 3.97 
CAl SER 516, Cp ASN 494 5.64 5.71 
CAl GLU 143, OEl SER 199 5.60 5.81 
CAl HOH 1074,0 3.53 3.79 N70, V351, H353, S355, K368, 
F512 
CAO* PHE 512, CE2 PRE 490 3.69 3.73 
CAO SER355, C~ SER333 4.00 3.98 
• Distances between equivalent atoms in the structure oftACE with lisinopril (PDB ID 1086). * More than one 
close proximity between the side chain moieties concerned (e.g. aromatic ring stacking); shortest interatomic 
distance quoted. 
3. 7. Determinants of lis W-S domain-selectivity 
3.7.1. C-domain-selectivity oflisW-S and selection against lisW-R 
The incorporation of the P2' Trp into lisW-S reduces the affinity for the N domain 
dramatically relative to the parent compound, lisinopril, with neither enantiomer inhibiting the 
N domain at concentrations of up to 500 ~M (Table 3.12). This reduction in affinity is similar 
to that observed with kA W and kAF, relative to kAP (Table 3.7). Both enantiomers of lis W 
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for the C domain is approximately 140-fold lower than that of lisinopril. This emphasises 
again the favourable contribution of a P2' prolyl moiety to high affinity binding. 
Table 3.12 Domain-selectivity of two enantiomers of novel inhibitor lisW, in comparison with the parent 









K."N domain (pM) a 
0.13 
> 500 b 
> 500 b 




a K; data were determined using the substrate z-Phe-His-Leu. b No inhibition detected up to a concentration of 
500 11M. 
The present crystallographic data suggest that the active site oftACE selects strongly for the S 
enantiomer, which showed the greater affinity for the C domain, and consequently the higher 
selectivity (Table 3.12). Selection against the R enantiomer is probably due to steric 
interference between the beta carbon of the PI side chain and the hydroxyl moiety of Y523, 
which were only 3.2 A apart when the R enantiomer was built into the active site. Y523 
makes a hydrogen bond with one of the zinc-binding inhibitor oxygens, and is conserved in 
both domains. This observation is in keeping with the activity of ACE on biological peptides, 
since the PI pseudo-Phe of lisW-S has the chirality of an L-amino acid, while that of lisW-R 
has D-amino acid chirality. The parent compound, lisinopril, shares this chirality. 
3.7.2. Interactions accounting for the domain-selectivity of lis W -S 
lis W -S makes contact with nine residues that differ between the N and C domains (Figure 
3.15; Tables 3.10 and 3.11). Two ofthese, E162 and D377 ofthe C domain, are close enough 
to the PI' Lys side chain amine nitrogen to make ionic interactions or weak hydrogen bonds 
(Table 3.10). E162 is replaced by the shorter D140 in the N domain, and D377 by the 
uncharged Q355, both substitutions which have previously been suggested to playa role in 
the domain-selectivity oflisinopril (Natesh et ai., 2004). 
In the S2' and S1 pockets, lisW-S contacts the same inter-domain substitutions that contribute 
to the C-domain-selectivity ofk:A W, namely E376D, V379S and V380T in the S2' pocket, and 
S516N and V518T in the S1 pocket (Figure 3.15). There is no steric clash with Y396 of the N 
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E413, which is replaced by 8119 in the N domain, comes within distant hydrophobic 
interaction distance of the PI Phe ring (Figure 3.15; Table 3.11). However since this residue 
is charged it is unlikely to contribute favourably to C-domain-selectivity. 
Because of the conformational change seen in the P2' moiety, the importance of the 82' 
interactions is likely to be different in comparison with kA W. For instance, V380 can be 
expected to play an important role in the affinity of this inhibitor since it stacks together with 
the P2' Trp and PI' Lys side chains. Equally, E376 is not likely to contribute favourably to 
binding to the C domain, since the Trp hydrogen bond is made directly to D415 and not to the 
water network as seen in kA W. 
The C-domain-selectivity oflisW-8 is thus probably due to favourable interactions with El62 
(PI'), D377 (PI'), E376 (P2'), V379 (P2'), V380 (P2'), 8516 (PI) and V518 (PI), which are 
substituted in the N domain. 
3.B. Water molecules in the active site oftACE 
It has been suggested that replacement of conserved active site waters could be used as a 
strategy for ACE inhibitor design (Corradi et al., 2007). Many of the water molecules 
contacting the inhibitors in these structures are conserved in other tACE co-crystal structures. 
Notably, the positions of waters 1006, 1016, 1058 and 1163 of the kA W structure (Tables 3.5 
and 3.6) are conserved in all of the published tACE co-crystal structures (PDB IDs 1086, 
lUZE, lUZF and 20C2) as well as the kAF and lisW-8 structures. In addition, waters 1020, 
1161, 1165 and 1169 of the kAW structure are conserved in all except the RXPA380 co-
crystal structure. 
Water 1165 of the kA W structure is particularly interesting since it is within hydrogen 
bonding distance of one of the zinc-binding inhibitor oxygens, the PI backbone amide (of 
kA W and kAF), the zinc ligand E411, Y523 which participates in stabilisation of the gem-
diolate, and R522 which is bound to the chloride ion CL2 (Figure 3.19). This water molecule 
thus seems to be important for substrate binding, and provides a possible explanation for the 
chloride dependence of the C domain (Wei et al., 1991), which has been shown to be linked 
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CL2 may serve to position this residue for optimal interaction with the substrate via water 
1165. 
Figure 3.19 Cartoon representation of conserved water molecule 1165 in the active site of the co-crystal 
structure of tACE-G 13 with kA W. The position of the oxygen atom of water 1165 is shown as a light pllq)le 
non-bonded sphere, and residues within hydrogen-bonding distance as yellow sticks. kA W is shown as cyan 
sticks, and potential hydrogen bonds to water 1165 are shown as dark blue dashed lines. The protein backbone is 
shown in yellow cartoon representation, the active site zinc ion as a grey sphere, chloride ion CL2 as a green 
sphere, and the zinc-binding residues H383 and H387 as yellow lines. 
The design of inhibitor compounds containing hydrogen bonding moieties that would occupy 
C-domain-specific water binding sites would enhance domain-selective binding. However 
comparison cannot be made with water sites in the N domain until an N domain structure is 
solved at high enough resolution to determine accurate water positions. 
3.9. Comments on affinity and suggestions for further inhibitor design 
3.9.1. The effect of the zinc-binding moiety 
It should be noted that the binding affinities of the inhibitors studied here are not of the same 
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nanomolar range (Acharya et al., 2003). This is likely due to a number of factors, including 
the weaker ketone zinc-binding moiety ofkAP and kA W, and the loss of the P2' Pro moiety. 
Because the ketone zinc binding moiety only takes on its zinc-binding hydrated state in the 
active site, it may prove that ketone inhibitors with the right side chain moieties are highly 
specific in vivo. The ketone group does have the disadvantage of eliminating the scissile 
amide nitrogen however, so that the carbonyl oxygen of A354 is left without hydrogen 
bonding partners in an arrangement which cannot favour binding. Replacement of the ketone 
with a different zinc binding group would allow the amide nitrogen to be replaced and 
introduce an additional hydrogen bond, however the resulting increase in affinity would not 
be domain-selective. 
3.9.2. Selectivity and affinity comparisons with other inhibitors 
Pro in the P2' position has been known to be favoured by both domains since the discovery of 
the BPPs and the development of the Ala-Pro analogue inhibitor captopril, and is thought to 
be an effect of the conformational constraint on the prolyl backbone (Michaud et al., 1999). 
This effect is particularly evident in the affinity of lis W -S for the C domain, which is 
approximately 140-fold lower than that of lisinopril, despite the fact that both compounds 
have a strong carboxyl zinc-binding group (Table 3.12). 
Although lisW-S and kA W do have lower affinities than their parent compounds with a P2' 
Pro, a P2' Trp moiety is not necessarily unfavourable for C domain binding, as shown by the 
high affinity of the C-domain-selective inhibitor RXPA380 (Georgiadis et al., 2004). This 
compound shares P2' Trp, PI Phe and P2 benzyl moieties with kA W, and is only two-fold 
more C-domain-selective, however its affinity for the C domain is approximately 230-fold 
higher than that of kA W (Georgiadis et ai., 2004). Drug compounds trandolaprilat, 
perindoprilat and ramiprilat, which bind with high affinity and slight C-domain-selectivity, 
also have bicyclic P2' groups combined with a proline-like backbone rigidity in the P2' 
position (Perich et al., 1994; Acharya et al., 2003). 
RXPA380 differs from kA W in its PI' pseudo-Pro moiety, phosphinic zinc-binding group and 
P2 pseudo-Phe. The PI' pseudo-proline moiety of RXPA380 may alter binding kinetics by 
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effects of binding, and perhaps additionally enforcing a P2' conformation that is unfavourable 
for binding to the N domain. The pseudo-proline probably also has higher affinity for the SI' 
sub site than the pseudo-glycine of kA W, as does the phosphinic zinc-binding moiety in 
comparison with a ketone group. The P2 pseudo-Phe, which is bulkier than the benzoyl 
moiety of kA W, probably also has an effect on binding, although this group should be more 
flexible than the CBz group and thus less likely to clash with Y369 ofthe N domain. 
Interestingly, the affinity of lis W -S for the C domain is approximately 10-fold lower than that 
ofkA Wand kAF, despite the additional polar interactions contributed by the PI' moiety. This 
may be the result of the absence of the favourable contribution of a P2 group and perhaps also 
the unfavourable conformational entropy contribution required to constrain the flexible Lys 
sidechain. 
3.9.3. Suggestions for future inhibitor design 
To take full advantage of the weak zinc-binding ketone group, C-domain-selectivity could be 
enhanced by increasing the affinity and selectivity of the side chain moieties. Attention 
should be paid to increasing the size of the P2' moiety, since it is evident from the structures 
that a P2' Trp or Phe does not fill the pocket sufficiently to take full advantage of all the 
potential domain-specific contacts. Trp, Phe and Arg at this position have been shown to 
favour the C domain (Dive et al., 1999; Acharya et al., 2003). Backbone rigidity might also 
be introduced as in trandolaprilat, perindoprilat and ramiprilat (de Lima, 1999). 
The close interaction between the PJ' and P2' moieties of lisW-S, in contrast with kA W in 
which the P2' Trp takes a different conformation, reveals cooperativity between side chains 
binding to the SI' and S2' pockets. The participation of the C-domain-specific residue, V380, 
in this interaction means that this characteristic could be exploited for enhanced selectivity 
and affinity. This could be achieved by introducing a fused moiety that would bind to both 
sites, or by experimenting with different combinations ofPl' and P2' moieties. 
The proximity of the PI and Pj' moieties to the zinc-binding group limits the degrees of 
freedom available to these side chains such that modifications to these groups which favour 
binding to one domain over the other, are likely to have a marked effect on domain-
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been shown to be cleaved more efficiently by the C domain than the N domain, and Pro, 
which resists hydrolysis (Bersanetti et aI., 2004). At the PI position, Phe, Leu and Arg have 
been shown to favour the C domain (Araujo et aI., 2000; Bersanetti et aI., 2004). 
Introduction of a nitrogen into the P2 benzoyl ring would allow the formation of an additional 
hydrogen bond with the carbonyl oxygen of A356. Since the benzoyl ring is in close 
proximity to F391 (Y369 in the N domain), this could enhance both affinity and domain-
selectivity. He, Ser and Lys at this position are also favoured by the C domain (Bersanetti et 
ai., 2004). 
The combination of some or all of these alterations, together with the use of a weak zinc-
binding group such as a ketone or phosphinate, should lead to the development of a new 
generation of C-domain-selective ACE inhibitors, presenting a different pharmacological 
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4.1. tACE-G13 co-crystal structures 
This study describes the first use of the minimally glycosylated tACE mutant tACE-G 13 for 
co-crystal structure determination in the drug design process towards the development of 
domain-selective ACE inhibitors for clinical use. The structures of novel C-domain-selective 
inhibitors kA W, kAF and lis W -S have been solved bound to the active site of tACE-G 13 
using X-ray crystallography, to 2.18, 2.17 and 2.30 A, respectively. No change was observed 
in the conformation of the protein component in comparison with previously determined 
structures, although an additional glycan residue could be built into the models for kA Wand 
kAF. 
4.2. Visualisation of the gem-diol transition state in ketone inhibitors 
The ketone zinc-binding moiety of kA W and kAF was found to be in the hydrated gem-diol 
state in the active site, equivalent to the transition state. The stabilisation of this state in the 
absence of a leaving amide group demonstrates the ability of the active site to stabilise the 
transition state transiently during peptide bond cleavage. These structures double the number 
of reported visualisations of the formation of a gem-diol hydrated state from a ketone 
precursor in the active site of an enzyme, the other two cases being co-crystal structures of 
carboxypeptidase A published 20 years ago and not deposited in the PDB (Christianson et at., 
1987; Shoham et ai., 1988). 
4.3. Selection for L-amino acid enantiomer of lis W 
Although two enantiomers of the lisinopril derivative, lisW-S and lisW-R, were used during 
co-crystallisation, only one isoform was detected in the active site. This suggests that the 
active site of ACE selects strongly for the lisW-S enantiomer, which has L-amino acid 
chirality in the P l position, probably by steric interference between the beta carbon of the PI 
side chain and the hydroxyl moiety of Y523. The D-amino acid enantiomer lisW-R is thus 
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4.4. Identification of inhibitor interactions important for domain-selectivity 
All three inhibitors take a similar backbone conformation to that observed in the co-crystal 
structures of tACE with other peptide inhibitors. The positions of their side chains allowed a 
detailed description of the S2, S1, SI' and S2' pockets and the identification of residues which 
could contribute to domain-selective binding. The moderate domain-selectivity of kAP can 
be attributed to four mutations in the PI and P2 pockets of the N domain relative to the C 
domain, while additional selectivity of the derivatives kA W and kAF in the P2/ pocket can be 
attributed to five inter-domain mutations. The lisinopril derivative inhibitor lisW-S derives its 
domain-selectivity from the same five P2' inter-domain mutations, as well as from mutations 
in the PI and PI' pockets. Several of these residues, E376, V380, Y391 and V518, have 
subsequently been confirmed by mutagenesis to be critical for the selectivity of kA W and 
kAF (Watermeyer et ai., Appendix D). 
4.5. Multiple conformations in the P/ position 
The P2' Trp moiety takes different conformations in kA W and lisW-S, due to hydrophobic 
stacking interactions of the Trp in the lisW-S structure with the PI' Lys moiety and V380. In 
kA W the Trp indole nitrogen makes a hydrogen bond to the water network, while in lisW-S 
the indole nitrogen is hydrogen-bonded directly to D415. Moreover, the Phe in this position 
in kAF was found to be partially disordered, and a glycerol molecule shares this pocket with 
the Trp ofkA W. This indicat s that the P2' pocket could accommodate still larger side chains, 
and highlights the importance of including hydrogen-bonding groups in this position for 
selective binding. 
4.6. Conserved water molecules 
Several conserved active site water molecules have been identified which might be displaced 
by hydrogen bonding groups in the next generation of domain-selective inhibitors. One of 
these, water 1165 of the kA W structure, is conserved in all the structures solved to date apart 
from the co-crystal structure with RXP A380. This water molecule connects the inhibitor 
backbone and crucial active site residues, E411 and Y523, via hydrogen bonds to R522, 
which is bound to chloride CL2. The positioning of this conserved water molecule may be 
critical for substrate binding, suggesting a reason for the R522-dependent chloride sensitivity 
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4.7. Suggestions for further inhibitor design 
From these results, proposals can be made for future inhibitor design. The potential of the 
ketone zinc-binding group should examined, since its weak zinc affinity means that the 
potency of the inhibitor depends to a greater extent on side-chain interactions. These side 
chain interactions might be made more C-domain-selective by, for example, exploitation of 
water positions or by introduction of previously-determined C-domain-selective residues. P2' 
residues should be bulkier and more rigid than Trp in order to take full advantage of selective 
interactions in this pocket, and consideration of cooperativity between the PI' and P2' 
positions might reveal novel means of achieving selective binding. 
4.8. Broader perspective 
By allowing the N domain to continue to function unimpeded, a drug compound targeted to 
the C domain of ACE is predicted to result in the alleviation of side effects associated with 
ACE inhibitor therapy. The results reported here represent a step along the pathway towards 
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Appendix A: Structure-based sequence alignment of the Nand C domains of 
human ACE 
The following table shows a sequence alignment of the N and C domains of human somatic 
ACE (GI: 23238217). The table was generated using the structural alignment of the N and C 
domain structures, as calculated by ALIGN (Cohen, 1997), as a reference for aligning residues 
in regions of low homology. The signal sequence is highlighted yellow, the N domain blue, 
the linker peptide light green, the C domain pink, and the stalk region with cleavage site (red 
X) orange. Stars under the alignment mark residues that are conserved between the N and C 
domains. The transmembrane and cytoplasmic domains are not highlighted. The conserved 
zinc-binding motif is printed in bold text and highlighted grey, and putative glycosylation 
sites are highlighted green. The last N-linked glycosylation site in the C domain has been 
shown to be unglycosylated (Yu et ai., 1997). Numbering does not include the signal peptide, 
which is cleaved off during processing. The sites of human SNPs are boxed. Testis ACE is 
identical to the C domain but has an additional 56-residue N-terminal signal sequence and 0-
glycosylated region (not shown). 
University of Cape Town
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Appendix B: Polar interactions of tACE and the N domain with inhibitors 
lisinopril, captopril, enalapril and 
The following table 
and RXP A3 80, with 
lllt(~rac:tlOl[1S of inhibitors lisinopril, captopril, enalapril 
of as detennined from their 
(Natesh et al., "-'V~.L"""U et al., 2006; Corradi et ai., 2007). 
University of Cape Town
N domain interactions with 
tACEatom a CAP atom. distance ENA atom. distance RXP atom. distance LPR atom, distance N domain atom b 
His 353 NE2 01 2.5 01 2.7 05 2.9 01 2.8 His 331 NE2 01 3.0 
Ala 354 0 Nl 3.0 Nl 2.9 Ala 332 0 Nl 2.6 
Glu3840E2 SI 3.1 02 2.7 04 2.6 02 2.7 Glu3620E2 02 2.7 
511 NZ 02 2.7 04 2.8 06 2.6 04 2.9 489NZ 04 2.7 
His 513 NE2 01 2.7 01 3.1 05 2.9 01 3.1 01 2.8 
5200H 02 2.7 04 2.6 06 2.6 04 2.6 4980H 04 3.2 
5230H 03 2.8 03 2.7 03 2.8 Tvr 501 OH 03 2.7 
Giu 162 OE2 02 2.7 N3 3.4 
Wat747 0 02 2.9 02 2.8 
Wat759 0 03 2.6 05 2.7 OXT 3.0 05 2.7 
Wat787 0 N3 3.0 
Wat835 0 N3 3.3 
Wat866 0 03 3.0 05 2.7 05 2.8 
Wat 10380 
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Appendix C: Structural alignment of ACE homologues 
The following tables present a structure-based multiple sequence alignment of hwnan ACE 
and ACE homologues that was generated using M-Coffee (Moretti et at., 2007). This server 
uses a combination of eight different multiple sequence alignment methods and outputs an 
alignment score based on the agreement between the methods. 
Table c.l. Overall alignment scores and key to Table C.2. 
Structure Code • Alignment score b 
Human tACE (C domain) I086A 
Drosophila melanogaster AnCE \J38A 
Human ACE N domain 2C6NB 
Human ACE2 IR4LA 
Rat neurolysin IIlIP 58 
Human thimet oligopeptidase IS4BP 58 
Escherischia coli dipeptidyl carboxypeptidase IY79 53 
Pyrococcus furiosus carboxypeptidase I lK9XD 52 
Thermus thermophifus carboxypeptidase 1 IWGZA 52 
Bacillus stearothermophilus oligopeptidase F 2HINA 40 
a Codes refer to the PDB ill and chain ID used for the alignment, where more than one chain was present in the 
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2C6NB 128 160 
2H1NA 154 184 
1086a 116 146 
1IlIP 195 242 
1S4BP 179 226 
1J38A 120 153 
1K9XD 98 127 
1R4LA 133 165 
1WGZA 98 127 
1Y79 190 ~. , .. --:;-~ ----- ...... -~- 242 
cons 217 • 270 
2C6NB 161 - -- -- 196 
2H1NA 185 -BLGYA 224 
1086a 147 182 
1IlIP 243 - - - -- 278 
1S4BP 227 - -- -- 262 
1J38A 154 189 
1K9XD 128 157 
1R4LA 166 201 
1WGZA 128 166 
1Y79 243 282 
cons 271 324 
2C6NB 197 - 239 
2H1NA 225 263 
1086a 183 - 225 
1IlIP 279 - 324 
lS4BP 263 - 308 
1J38A 190 - 232 
1K9XD 158 - 193 
1R4LA 202 - 253 
1WGZA 167 - 202 
1Y79 283 - 327 
cons 325 378 
2C6NB 240 287 
2H1NA 264 284 
1086a 226 273 
1I1IP 325 ------KySV------------DQBSLKBY 360 
lS4BP 309 344 
1J38A 233 280 
1K9XD 194 238 
1R4LA 254 301 
1WGZA 203 245 
1Y79 328 - LKPy' 358 
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PROBING THE BASIS OF DOMAIN-DEPENDENT INIDBITION USING NOVEL 
KETONE INIDBITORS OF ANGIOTENSIN-CONVERTING ENZYME 
Jean M. WaterlIlleyer!, Wendy L. Kroger!, Hester G. O'Neill!, B. Trevor Sewell l , 
Edward D. Sturrock l 
IDivision of Medical Biochemistry, Institute oflnfectious Disease and Molecular Medicine, 
University of Cape Town, Observatory, 7925, South Africa 
Running head: Domain·selectivity of ketone ACE inhibitors 
Address correspondence to: Edward David Sturrock, Division of Medical Biochemistry, 
Wernher Beit Building North, University of Cape Town, Observatory, 7925, South Africa. 
Fax: +27 21 4066470; Email: Edward.Sturrock@uct.ac.za 
The atomic coordinates and structure factors (codes 3BKK and 3BKL) have been deposited in 
the Protein Data Bank, Research Collaboratory for Structural Bioinforrnatics, Rutgers 
University, New Brunswick, NJ (http://www.rcsb.org/). 
Human angiotensin-converting enzyme 
(ACE) has two homologous domains, the 
Nand C domains, with differing 
substrate preferences. X-ray crystal 
structures of the C and N domains 
complexed with various inhibitors have 
indicated active site residues that might 
be important for the molecular basis of 
this selectivity. However it is unclear to 
what extent the different residues 
contribute towards substrate domain-
selectivity. Here, co·crystal structures 
of human testis ACE, equivalent to the 
C domain, have been determined with 
two novel C-domain-selective 
keto methylene inhibitors, (5S)-5-[ (N-
benzoyl)aminoJ-4-oxo-6-phenyl-
hexanoyl-L-tryptophan (kA W) and (5S)-
5-[ (N -benzoyl)amino J-4-oxo-6-phenyl-
hexanoyl-L-phenylalanine (kAF). The 
ketone groups of both inhibitors bind to 
the zinc ion as a hyd!I'ated geminal 
diolate, demonstrating the ability of the 
active site to catalyse the formation of 
the transition state. Moreover, active 
site residues involved in inhibitor 
binding have been mutated to their N 
domain counterparts and the effect of 
the mutations on inhibitor binding has 
been determined. The C-domain-
selectivity of these inhibitors was found 
to result from interadions between 
bulky hydrophobic side chain moieties 
and the C-specific residues F391, V518, 
E376 and V380 (numbering for testis 
ACE). Mutation of these residues 
decreased the affinity for the inhibitors 
4- to 20-fold. T282, V379, E403, D453, 
and S516 did not contribute individually 
to C-domain-selective inhibitor binding. 
These data emphasise the importance of 
key S], S2 and S2' residues for inhibitor 
domain-selectivity. 
The occurrence of two homologous 
active sites in one polypeptide chain is a 
rare phenomenon, thought to come about 
by gene duplication leading to the 
development of new activities (1,2). 
Human somatic angiotensin-converting 
enzyme (ACE)I is one such case, having 
two 55% identical domains, Nand C, each 
containing an active site with a zinc 
binding motif, HEMGH (3,4). ACE is a 
key target for the treatment of hypertension 
because of its role in increasing blood 
pressure via the renin-angiotensin system 
(5,6). 
Further examples of such two-domain 
enzymes are sucrase isomaltase (SI) and 
lactase-phlorizin hydrolase (LPH), both 
involved in sugar metabolism (7,8). In 
these enzymes the homologous domains, 
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distinct substrates. The domains of SI 
cleave related disaccharides sucrose and 
isomaltose, while LPH cleaves lactose and 
the glucoside phlorizin. In the case of 
LPH, mechanism-based domain-selective 
inhibitors were used to elucidate the 
activities of the two domains (9). Other 
examples of enzymes containing 
homologous active domains include 
adenylyl transferase of Escherischia coli 
(10), which catalyses the adenylylation and 
deadenylylation of glutamine synthetase, 
and protein disulphide isomerase (11), 
which catalyses disulphide bond oxidation, 
reduction and isomerisation. 
In all of these examples, a few active 
site substitutions correspond to 
significantly different, but functionally 
complementary, substrate specificities for 
the homologous domains. ACE differs 
from these enzymes in that its activity is 
not highly specific, with each domain 
being able to cleave a range of peptide 
sequences, however the efficiency of 
cleavage varies between domains and 
some substrates are domain-specific (12-
14). The N and C domains of ACE also 
differ in chloride dependence (4,15) and 
thermo stability (16). 
These differences between the domains 
make it appealing to develop an 
antihypertensive ACE inhibitor therapy 
that selectively targets one domain. The C 
domain has been shown to produce the 
potent vasopressor angiotensin II from 
angiotensin I more efficiently than the N 
domain, in vivo (17-19). Moreover, build-
up of bradykinin, a substrate of both 
domains, has been implicated in a number 
of ACE inhibitor-related side effects (20-
22). It has been suggested that a C-
domain-selective ACE inhibitor would 
reduce blood pressure while allowing the 
N domain to maintain physiological 
bradykinin levels, resulting in more 
effective treatment of hypertension with 
reduced side effects (14,23). 
Keto-ACE (hereafter referred to as 
kAP), an analogue of the tripeptide ACE 
inhibitor Bz-Phe-Gly-Pro, has been shown 
106 
to be 26 to 34 times more selective for the 
C domain with a variety of substrates 
(24,25). Using kAP as a platform and 
making C-terminal substitutions, our group 
has synthesised a number of novel 
compounds. Two of these, (5S)-5-[(N-
benzoyl)amino ]-4-oxo-6-phenyl-hexanoyl-
L-tryptophan (kA W) and (5S)-5-[(N-
benzoyl)amino J-4-oxo-6-phenyl-hexanoyl-
L-phenylalanine (kAF) (Figure 1), are 
highly C-selective (26). 
In this study, we determine the crystal 
structures of human testis ACE (tACE), 
which is equivalent to the C domain of 
ACE, in complex with the novel domain-
selective inhibitors kA W and kAF. In 
addition, we assess the effect of a number 
of active site mutations on inhibitor 
binding. This combined structural and 
kinetic approach allows the determination 
of the extent to which particular residues 
contribute to the C-domain-selectivity of 
these inhibitors. 
EXPERIMENTAL PROCEDURES 
tACE constructs- A fully N-
glycosylated tACE mutant, tACEL).36NJ, 
truncated after S625 and lacking the 36 0-
glycosylated, N-terminal residues (27) was 
cloned into the BamHI and EcoRI 
restriction sites of pcDNA3.1(+) 
(Invitrogen) for expression purposes. A 
minimally glycosylated form of this 
mutant, tACE-G 13 (28), was used for 
crystallisation. 
Inhibitors- Inhibitors kAP, kA W and 
kAF were synthesised previously (26,29). 
Stocks were made by dissolving inhibitors 
in a small volume of DMSO and then 
diluting in water or huffer, for enzyme 
assays. 
Cloning and mutagenesis- Site-directed 
mutagenesis was performed on an 
SphI-EcoRI fragment of the C domain 
coding region in pGEM11zf(+) (Promega) 
as described previously (30), converting 
selected active site residues to their N 
domain counterparts. Oligonucleotides 
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synthesised by Inqaba Biotech, South 
Africa, and reagents used for site-directed 
mutagenesis were supplied by Promega. 
Colonies were screened with appropriate 
restriction enzymes, and positive clones 
were confirmed by nucleotide sequencing. 
C domain mutants were constructed in 
pcDNA3.1 + for protein expression. 
Heterologous expression and 
purification- tACE constructs were 
expressed in Chinese hamster ovary cells 
and purified by Sepharose-lisinopril 
affinity chromatography, as described 
previously (28,31). ACE activity was 
detected using a fluorogenic assay with 
substrates Hippuryl-Histidyl-Leucine 
(HHL; Sigma) or z-Phenyl-Histidyl-
Leucine (z-FHL; Sigma) (32). Pooled 
fractions were dialysed against 2 L 0.5 mM 
Hepes (PH 7.5) overnight. tACE-G 13 was 
concentrated to 1-5 mglmL for 
crystallisation using an Amicon Ultra-4 
spin column (Millipore). The purified 
protein's molecular weight and purity were 
assessed using SDS-PAGE. 
Crystallisation- Crystals were grown 
by vapour diffusion at 16 °C in hanging 
drops comprising 2 III protein (1.45 
mglmL) or protein/inhibitor solution mixed 
with 2 III reservoir buffer over 1 ml 
reservoirs covered with 500 Jll oil (3 parts 
paraffm, 2 parts silicon oil, Hampton) (33). 
Inhibitor-free tACE-G 13 microcrystals 
grew within two weeks over reservoirs 
containing 10 mM sodium acetate (PH 4.7; 
Merck), 15% PEG 4000 (Fluka) and 10 
IlM ZnS04. Co-crystals of tACE-G 13 
with inhibitors were grown by streak-
seeding these microcrystals into fresh 
drops containing inhibitor mixed with 
tACE-G13, over reservoirs containing a 
higher concentration of sodium acetate (30 
mM) but otherwise identical to the 
reservoirs used for growing microcrystals. 
Diffracting crystals were grown within two 
weeks in drops containing 1 mM kA W 
with 1 mglml tACE-G 13 and 1.25 mM 
kAF with 1.4 mglml tACE-G 13. 
Data collection and processing- Data 
were collected at 100 K from a single 
107 
crystal per inhibitor at beamline 
BM14(UK) of the European Synchrotron 
Radiation Facility, Grenoble, France, using 
a wavelength of 1.033 A. 
Data were processed using HKL2000 
(34) and phasing was carried out with 
EPMR 2.5 (35) using protein atoms from 
the crystal structure of tACE-G 13 (Protein 
Data Bank (PDB) code 2IUL) as a model. 
Model building was carried out using 
o v9. 0.7 (36), against 2Fobs-FeaZc, Fobs-FeaZe 
and composite omit maps (simulated 
annealing with 5% omission), calculated 
using eNS (37). Waters were added using 
the waterjJick protocol of CNS (37), 
followed by visual inspection. Ligand 
molecules were built using PRODRG (38) 
and ARPlwARP (39). Maximum 
likelihood minimization and simulated 
annealing of selected residues was carried 
out using CNS (37). PROCHECK and 
SFCHECK from the CCP4 programme 
suite (39), and Molprobity (40) were used 
for model validation. Hydrogen bonds and 
close contacts were identified using 
HBplus (41). Figures were generated 
using Pymol vO.99 (DeLano Scientific, 
Palo Alto, CA, U.S.A). 
Substrate hydrolysis- The hydrolysis of 
the fluorogenic peptide Abz-FRK(Dnp)P-
OH (a kind gift from Dr Adriana Carmona) 
was characterised in a continuous assay at 
25 °C under initial rate conditions, by 
measuring fluorescence at Aex = 320 nm 
and Aem = 420 nm. A substrate 
concentration range of 0 - 12 IlM was 
added to the reaction mixture of 50 mM 
Hepes buffer, pH 6.8, containing 200 mM 
NaCl, 10 JlM ZnCh and an enzyme 
concentration of 0.2 nM. Kinetic constants 
were calculated using the direct linear plot 
method (42,43). 
Inhibition kinetics- ACE constructs (2 
nM) were incubated with an appropriate 
concentration range of inhibitor in 50 mM 
Hepes buffer, pH 6.8, containing 200 mM 
NaCl and 10 JlM ZnCh, at ambient 
temperature for 60 min. 20 JlL of the 
enzyme-inhibitor mixture were added to a 
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pH 6.8, containing 200 mM NaCI, IO!lM 
ZnCb and 4 or 8 !lM 
Abz-FRK(Dnp)P-OH, to make up a total 
volume of 300 !lL, in triplicate. Residual 
enzyme activity was monitored by 
determining fluorescence at !vex = 320 nm 
and !vern = 420 nm, at 25°C. Inhibition 
constants were calculated using the Dixon 
method (44). 
RESULTS 
Co-crystal structures of tACE-G 13 with 
novel inhibitors- The C-domain-selective 
compounds kA W and kAF were derived 
from the moderately domain-selective 
ketone ACE inhibitor, kAP, by substitution 
of the P2' group (Figure 1) (26,29). In 
order to understand the mechanism of 
domain-selectivity, we determined co-
crystal structures of these two novel 
inhibitors with tACE, which is identical in 
sequence to the C domain. To facilitate 
crystallisation we used a minimally 
glycosylated construct, tACE-G 13, 
containing only two intact glycosylation 
sites (28,45). Structures were solved by 
molecular replacement and refmed to final 
crystallographic R-factors of20.0% n both 
cases. Data processing and refinement 
statistics are presented in Table 1. 
In both the kA W and kAF co-crystal 
structures, the protein component is in an 
identical conformation to the inhibitor-free 
tACE-G 13 structure (PDB code 2IUL), as 
evidenced by all-atom Lm.s. deviations of 
0.61 A and 0.67 A, respectively. Overall, 
this structure is mostly alpha helical and 
ellipsoid in shape, containing two chloride 
ions, with the zinc ion buried deep in the 
active site cleft. As in the unliganded 
structure, glycan residues are present at the 
two intact glycosylation sites in tACE-
G13, N72 and NI09, where there is 
evidence of glycan-mediated stabilisation 
of the lid helices, as was observed 
previously (45). 
One inhibitor molecule is bound to the 
active site of each tACE-G 13 molecule, in 
an extended conformation (Figure 2) 
08 
similar to that seen for the phosphinic 
peptide inhibitor, RXPA380 (46). Weak 
density around the P2' side chain of kAF 
indicates a degree of flexibility, which is 
also evidenced by the higher B-factors of 
these atoms. These inhibitors have a 
ketone zinc-binding moiety analogous to 
the carbonyl oxygen of the scissile peptide 
bond, however the density maps 
surprisingly indicate the stabilisation of a 
hydrated geminal diolate (gem-diol) 
transition state at the active site, in which 
two oxygens are attached to the carbonyl 
carbon analogue (Figure 3). The zinc co-
ordination distances for the gem-diol 
oxygens are 2.23 and 2.42 A for kA W and 
2.41 and 2.52 A for kAF (see 
supplementary Table 1). 
kA W makes nine polar contacts 
(potential hydrogen bonds and ionic 
interactions) with seven protein side 
chains, while kAF makes nine polar 
contacts with six protein side chains, the 
difference being small changes in the 
orientations of Q281 and E384 
(Supplementary Table 1). Additional 
hydrogen bonds are made with four water 
molecules, whose positions are conserved 
between the structures, as well as with a 
glycerol molecule derived from the cryo-
protectant in the kA W structure. The 
conformation of the Trp moiety of kA W 
does not appear to be effected by the 
presence of the glycerol, since it takes the 
same conformation as the P2' Trp of 
RXP A380, which does not have a glycerol 
in this position. Moreover, no glycerol-
like density was present at this position in 
composite omit maps generated using the 
RXP A380 structure factors from the PDB. 
These solvent molecules form part of a 
hydrogen bonding network connecting the 
inhibitor to other active site residues and to 
the bulk solvent (Figure 4). 
Close contacts are also observed 
between the nonpolar moieties of the 
inhibitors and l7 active site residues as 
well as a number of water molecules (11 
and 13 for kA W and kAF, respectively), 
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kA W (Supplementary Table 2). Some of 
these active site residues (T282, S355, 
V379, V380, H387, F457, F512, V518 and 
F527) could contribute favourably to 
binding entropy by the hydrophobic effect, 
while others (Q281, H353, A354, E384, 
D415 and the water molecules) are polar or 
charged groups, and some (H383 and 
Y523) make both favourable and 
unfavourable contacts. 
Nine residues that interact with kA W 
and kAF directly, or indirectly via solvent 
atoms, are replaced with a different amino 
acid in the N domain and may thus 
contribute to the domain-selectivity of 
these ketone inhibitors (Figure 2). 
Kinetic analysis of active site ACE 
mutants- In order to investigate the role of 
the nine active site residues that differ 
between domains, a series of tACE 
mutants was generated in which these 
residues were converted to their N domain 
counterparts (Table 2). 
Using the substrate Abz-FRK(Dnp)P-
OH under the conditions described, kA W 
shows strong C-selectivity, having almost 
1300-fold greater affinity for the C domain 
than for the N domain (Table 2). The 
greatest decreases in affmity for kA W 
observed among the mutants were with the 
S1 pocket V518T and S2 F391Y mutants 
(Table 2, Figure 5). The mutants E403R 
and S516N in these pockets displayed no 
change in affinity for kA W relative to 
wild-type tACE. In the S2' pocket mutants 
E376D and V380T demonstrated similar 
increases in K i, while the V379S mutation 
caused an increase in affinity for the 
inhibitor. The T282S and D453E mutants 
displayed similar K/ s to that of the wild-
type C domain (Table 2, Figure 5). 
The selectivity ofkA W is only two-fold 
lower than that ofRXPA380, which shares 
a P2' Trp, PI Phe and P2 benzyl moiety 
with kA W (14). However, the affinity of 
kA W for the C domain is approximately 
230-fold lower than that of RXPA380, 
which has a C domain Ki of 3 nM (14). 
These data for RXPA380 were determined 
under the same reaction conditions as those 
109 
used here, but using a different fluorogenic 
peptide substrate, Mca-ASDK-DpaOH 
(14). No change in selectivity was 
observed when using Abz-FRK(Dnp)P-OH 
(data not shown). 
kAF was also shown to be highly C-
domain-selective under these conditions, 
with a C domain Ki of 0.83 !lM (Table 2). 
No inhibition of the N domain was 
observed using up to 500 !lM kAF and at a 
range of chloride concentrations. Due to 
the limited solubility of this compound, 
inhibition could not be tested at higher 
concentrations. The V 518T mutation 
again displayed the greatest decrease in 
affmity for kAF, while small decreases in 
affinity were also observed for the F391, 
E376D and V380T mutants (Table 2, 
Figure 5). 
In order to understand the domain-
selectivity of the parent compound, kAP, 
we tested the effects of the F391 Y, S516N 
and V518T mutations in the S1 and S2 
pockets on the binding affinity of this 
inhibitor. kAP had a 30-fold higher 
affinity for the C domain than for the N 
domain (Table 2). Notably, the F391 Y 
mutation in the S2 pocket caused an 8-fold 
decrease in affinity relative to the wild-
type C domain, while the S I V 518T mutant 
had a Ki similar to that observed for the N 
domain. The S516N substitution resulted 
in comparable binding affinity to that of 
the wild-type C domain (Table 2). 
DISCUSSION 
As an enzyme with two homologous 
catalytically active domains, ACE is an 
intriguing drug target. Differences in the 
activity profiles of the domains, 
particularly with reference to the cleavage 
of angiotensin I and bradykinin, render it 
desirable to design selective inhibitors to 
the C domain, however the high homology 
between the domains makes this a complex 
problem. That domain-selective inhibition 
is possible is evident from the selectivity 
of some known substrates and inhibitors, 










CHAPTER 6: Appendices 
strongly domain-selective phosphinic 
peptide inhibitors RXPA380 and RXP407 
(13,14,24,47,48). We have recently 
developed new C-selective inhibitors kA W 
and kAF, based on the moderately domain-
selective inhibitor kAP (26,29). 
In zinc metalloproteases, peptide bond 
hydrolysis is thought to occur via a 
tetrahedral transition state which forms 
upon nucleophilic attack of the carbonyl 
carbon by an activated zinc-bound water 
molecule at the active site (49,50). This is 
followed by protonation of the scissile 
amide nitrogen and subsequent peptide 
bond cleavage. We found that the 
replacement of the scissile peptide bond 
nitrogen with a carbon atom in these 
inhibitors (Figure 1) led to the trapping of 
the tetrahedral gem-diol transition state at 
the active site (Figure 3). 
The hydrated transition state has been 
observed previously in the structures of 
carboxypeptidase A (CPA) co-crystallised 
with ketomethylene inhibitors 5-
benzamido-2-benzyl-4-oxopentanoic acid 
(BOP) and 5-amino-(N-t-butoxycarbonyl)-
2-benzy 1-4-oxo-6-phenylhexanoic acid 
((51,52); structures not available in the 
PDB). In these structures, the hydrated 
form of the ketone was observed at the 
enzyme active site despite the fact that this 
form does not occur «1 %) in aqueous 
solution. Active site stabilisation of gem-
diols is commonly observed in co-crystal 
structures with aldehyde inhibitors and 
inhibitors containing activated 
electrophilic ketones, with examples from 
the PDB including co-crystal structures of 
leucine aminopeptidase (code lLAN) (53), 
CP A (code 1 CBX) (54), endothiapepsin 
(code 10DI) (55) and human GAR 
transformylase (code INJS) (56). 
However, the hydration of a ketone in the 
absence of an activating group, as seen 
here, has to the best of our knowledge only 
been reported in two other crystal 
structures, those of CPA mentioned above. 
The gem-diol oxygens in the structures 
of kA W and kAF at the active site of 
tACE-G 13 have partial negative charges 
110 
and interact with the active site zinc ion 
(Supplementary Table 1), in similar 
positions to the carboxyl oxygens oftACE-
bound lisinopril and enalaprilat (PDB 
codes 1086 and 1UZE). Y523 and E384, 
which has been proposed to shuttle a 
proton between the attacking nucleophilic 
water and the leaving amide, also make 
hydrogen bonds with the gem-diol (Figure 
3). In the structure of CPA bound to BOP 
the gem-diol has longer zinc-coordinating 
distances (2.51 and 2.91 A; (51)) than 
those observed here, however it is clear 
from the overlap of the gem-diol oxygens 
of kA W and kAF with the zinc-binding 
oxygens of other inhibitors that these 
positions are characteristic of the ACE 
active site. 
Thus, we have shown that in the 
absence of a leaving amide nitrogen, the 
catalytic residues of ACE are able to 
stabilise the tetrahedral transition state. 
This stabilisation probably plays a 
transient role in overcoming the energy 
barrier between substrate and products 
during catalysis. 
The ketone zinc-binding moiety of kAP 
and its derivative inhibitors has lower 
affinity for the active site zinc ion than the 
carboxyl, sulphydryl and phosphinyl 
groups of other previously-studied 
inhibitors (46,57,58). This results in a 
situation similar to the binding of a natural 
substrate, with the affinity of the inhibitor 
depending to a great extent on the 
contributions of other groups. These 
inhibitors are thus suitable tools for 
investigating the contributions of moieties 
other than the zinc ion to inhibitor binding. 
kAP has a 30-fold higher affinity for the 
C domain than for the N domain (Table 2). 
This domain-selectivity does not reside in 
the PI' position since there is no PI' side 
chain in kAP, or in the P2' moiety, since 
Pro at this position does not favour binding 
to one domain (59). Moreover, from the 
co-crystal structures of tACE and the N 
domain with lisinopril (PDB codes 1086 
and 2C6N, respectively), one can see that a 
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domain equivalent, Y501, making no 
interactions with residues that differ 
between domains. Thus, the modest 
selectivity of kAP must be attributed to its 
PI and P2 moieties, which are retained in 
kAWandkAF. 
The S 1 and S2 pockets of the N and C 
domains differ in four residues that lie 
within 6 A of kA W and kAF, of which 
S516, V518 (SI pocket) and F391 (S2 
pocket) make hydrophobic contacts with 
the inhibitor PI and P2 side chains. These 
are replaced by the charged and polar 
residues N494, T496 and Y396, 
respectively, in the N domain (Figure 2). 
Of these substitutions, F391 Y and 
V 518T were shown by our kinetic analysis 
to be important for the selectivity of kAP, 
reducing affinity 8-fold and 26-fold, 
respectively. The F391 Y mutation 
introduces a hydroxyl group into the S2' 
pocket, which would result in steric 
hindrance of the binding of the P2 
carboxybenzoyl moiety of kAP. This 
substitution has been identified as 
potentially contributing to the C-domain-
selectivity of the phosphinic peptide 
inhibitor RXP A380, which also has a 
benzoyl group at this position (46). 
The effect of the V518T mutation is not 
steric, however the association of the PI 
Phe side chain with T496 of the N domain 
is probably made unfavourable by the 
displacement of any water molecules 
hydrogen-bonded to the hydroxyl moiety, 
which would be necessary for binding of 
the bulky phenyl group. Displacement of 
waters around V518, in contrast, would 
result in a favourable increase in entropy. 
This S 1 sub site alteration may explain the 
moderate C-selectivity of lisinopril and 
enalaprilat, which also have P I phenyl 
groups, as well as the observation that a 
bulky PI moiety confers C-domain-
selectivity (60). 
The C-domain-selectivity of kAP is thus 
due to sterically and entropically 
favourable hydrophobic interactions 
between the bulky hydrophobic PI and P2 
benzoyl moieties and F391 and V518, 
111 
which are replaced with polar groups in the 
N domain. These substitutions also had a 
dramatic effect on the binding of kA W and 
kAF (Figure 5). 
The single residue replacement of Trp 
for the P2' Pro of kAP reduces the affinity 
of kA W for the N domain dramatically, 
making it approximately 40-fold more C-
selective than kAP (Table 2). Although 
the mutation ofV518 to Thr did result in a 
large decrease in affinity for kA W (14-
fold), the Ki did not equal that of the N 
domain, as occurred with kAP, suggesting 
that other factors play a role in the 
selectivity of this inhibitor (Table 2). 
In the crystal structure, the P2' Trp 
indole nitrogen of kA W makes a hydrogen 
bond to a highly ordered glycerol 
molecule, which is hydrogen-bonded to 
T282, Q281, N277, E376, and a network 
of water molecules in the S2' sub site 
(Figure 4). Since this glycerol is derived 
from the cryo-protectant used for data 
collection, crystal growth must have 
occurred in its absence, suggesting that a 
water molecule was the original acceptor 
for the Trp hydrogen bond. 
In addition to this hydrogen bond, the 
Trp interacts closely with a hydrophobic 
patch created by T282, F457, F527 and 
Y523 on one side, and with H383, V379, 
V380 and a water molecule on the other 
side (Figure 2, Supplementary Table 2). 
Four of these ten residues, T282, E376, 
V379 and V380, are substituted in the N 
domain (Figure 2). 
From the kinetic data, the enhanced 
selectivity of kA W can be attributed to 
E376 and V380, with the E376D and 
V380T mutations demonstrating 
approximately 4-fold decreases in affinity 
(Table 2, Figure 5). Since E376 interacts 
with the Trp indole N indirectly via the 
glycerol (or water network), the effect of 
the E376D mutation is probably a result of 
the weakening of this interaction due to the 
lengthening of the distance between the 
negatively charged group and the indole 
nitrogen. In the N domain structure (PDB 
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from the active site. The V380T mutation 
amounts to the introduction of a polar 
group in close proximity to the Trp ring, 
similar to the S 1 V 518T mutation. The 
overall low affinity of the N domain for 
kA W is thus probably the combined effect 
of these two S2' mutations together with 
those in the PI and P2 pockets. 
Interestingly, the V379S mutant 
actually displays considerably higher 
affinity for kA W than the wild-type. This 
effect is not readily explained by the 
crystal structure but may be due to a 
rearrangement of side chains in the S2' 
pocket, possibly leading to the formation 
of a water-mediated hydrogen bond 
between the Ser and the Trp indole N. 
This is supported by the observation that 
this mutant did not have increased affinity 
for kAF, which lacks a P2' hydrogen-
bonding moiety (Table 2). The C-domain-
like affinity of the double VV/ST mutant 
can be explained as the net result of the 
affinity-decreasing effect of the V380T 
mutation and the large affinity-increasing 
effect of the V379S mutation. 
kAF is also strongly C-selective, 
exhibiting no inhibition of the N domain 
up to 500 JlM inhibitor. Like the Trp of 
kA W, the P2' sidechain contacts V379 and 
V380, as well as the conserved 
hydrophobic residues H383, Y523, F527 
and F457, but many of these contacts are 
more distant than those of kA W because of 
the smaller size of the Phe side chain 
(Figures 2 and 4, Supplementary Table 2). 
Moreover, the aromatic ring is unable to 
make a hydrogen bond to the water 
network, and in place of the glycerol 
moiety seen in the kA W structure, a ring of 
ordered waters is present, interacting with 
the polar residues beyond (Figure 4; 
Supplementary Table 2). The effect of the 
smaller size of this side chain, together 
with the lack of a hydrogen-bonding 
moiety, is evident in the disorder of this 
group in the crystal structure, in 
comparison with the Trp of kA W, which 
displays lower B-factors and clearer 
density (Figures 2 and 4). 
l12 
As with kA W, the mutation of V380 
and E376 to T358 and D354, respectively, 
contributes to the low affinity of this 
inhibitor for the N domain (Table 2). The 
selectivity of kAF is thus the combined 
effect of these mutations, together with the 
clash of the bulky hydrophobic PI and P2 
moieties with F391 and V518. 
From this investigation, it can be 
concluded that the C-domain-selectivity of 
the kAP P2' derivatives kA W and kAF 
results from interactions between their 
bulky hydrophobic side chain moieties and 
the C-domain-specific residues F391 (P2), 
V518 (PI)' E376 and V380 (P2'). 
Candidate substituted residues T282, 
V379, E403, D453, and S516 do not 
individually contribute favourably to the 
binding of these inhibitors. 
It should be noted that the binding 
affinities of these inhibitors are not of the 
same order of magnitude as those of 
currently available drugs such as lisinopril 
which have Ki values in the low nanomolar 
range (60). Replacing the zinc-binding 
ketone with another group having higher 
affinity for the zinc ion would probably 
improve the overall affinity, however this 
would be a non-selective effect. An 
approach more suited to domain-selective 
inhibitor design would be to increase the 
affinity and selectivity of the inhibitor side 
chain moieties while maintaining the 
ketone group. Attention should be paid to 
increasing the size of the P2' moiety, since 
it is evident from the structures that a P2' 
Trp or Phe does not fill the pocket 
sufficiently to take full advantage of all the 
potential domain-specific contacts. Novel 
domain-selective effects might also be 
achieved by introducing a PI' side chain 
into these inhibitors. 
These data will likely aid in the process 
of structure-based drug design of domain-
selective ACE inhibitors suitable for 
clinical use, ideally eliminating some of 
the side effects associated with current 
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FOOTNOTES 
1 ABBREVIATIONS: ACE, angiotensin-converting enzyme; sr, sucrase-isomaltase; LPH, 
lactase-phlorizin hydrolase; kAP, keto-ACE; kA W, (5S)-5-[(N-benzoyl)amino]-4-oxo-6-
phenyl-hexanoyl-L-tryptophan; kAF, (5S)-5-[(l'IJ-benzoyl)amino ]-4-oxo-6-phenyl-hexanoyl-
L-phenylalanine; tACE, testis angiotensin-converting enzyme; tACE-G 13, minimally 
glycosylated tACE mutant; DMSO, dimethyl sulphoxide; HHL, Hippuryl-Histidyl-Leucine; 
z-FHL, z-Phenyl-Histidyl-Leucine; PDB, Protein Data Bank; CPA, carboxypeptidase A; 
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FIGURE LEGENDS 
Figure 1. Chemical structures of kAP and its derivatives kA W and kAF, showing residue 
positions relative to the zinc-binding group (P2, PI, PI', P2')' 
Figure 2. Stick representation of kA W (A) and kAF (B) in the active site, showing the 
first Fobs-Fcalc difference density map (purple mesh) into which the inhibitor model was built, 
contoured at a level of 3 cr. The position of the active site zinc ion (ZN2) is shown as a green 
non-bonded sphere, indicated with an arrow, and zinc-binding residues are shown as black 
lines in the foreground. Clear density for a tetrahedral gem-diol hydrated form of the zinc-
binding ketone moiety is evident. Inhibitor-contacting residues that differ between domains 
are shown in yellow (tACE residues from the co-crystal structure) and purple (l\J domain 
residues from the aligned N domain structure, PDB code 2C6F). Residue labels are given as 
tACEIN domain, and the P l , P2 and P2' moieties are labeled. In A, the active site-associated 
glycerol (GOL) and acetate (ACT) molecules are also shown as yellow sticks in Fobs'"'Fcalc 
difference density. 
Figure 3. Stabilisation of the hydrated transition state in the active site. The ketone 
inhibitor kA W (blue sticks) in Fobs-Fcalc density (purple mesh, contoured at 3 cr) has been 
orientated to show the gem-diol moiety coordinating the active zinc ion (grey sphere). The 
zinc-coordinating residues and those involved in stabilising the intermediate are labeled and 
shown as yellow sticks. 
Figure 4. Close-up views of the S2' pocket with kA W (A) and kAF (B), showing the 
solvent network. The inhibitors and glycerol are shown as yellow sticks in Fobs'"'Fca/c 
difference density (purple mesh), contoured at 3 cr. The active site zinc ion is shown as a 
green nonbonded sphere, water molecules as light blue nonbonded spheres, and solvent 
hydrogen bonds as blue dashed lines. 
Figure 5. Comparison of the relative binding affinity of tACE active site mutants for 
ketone inhibitors kA W (black bars) and kAF (grey bars), with that of wild type tACE (C 
domain). Values above the line represent an N-domain-like decrease in affinity relative to 
that oftACE. The N domain Ki was 1258- and >602-fold higher than that oftACE for kA W 
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Table 1. X-ray data collection and processing statistics. 
Data set kAW 










Rmerge (%) a, b 
No. reflections in working set (test set) 
Rcryst (%) a,c 
Rfree (%) a,d 
Mean B factor (A2) [min. - max.J 
No. solvent atoms 
No. protein atoms e 
No. metal ions 
No. inhibitor atoms 
No. glycan atoms 



























































• Values in parentheses refer to the highest resolution shell; b Rmerge = [~h~j I~(h) - (1(h) I ] I ~h~J 1~(h)I, where 1,{h) 
and (l(h» are the ith and the mean measurements of the intensity of reflection h, respectively. C Rerys!::: Lh lFa-
Fell Lh Fa, where Fa and Fe are the observed and calculated structure factor amplitudes of reflection h of the 
working set, respectively; d Rfree is equal to Rerys! for h belonging to the test set of reflections; e excluding 
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Table 2. Kinetics of inhibition by kA W and kAP, of tACE mutants having active site 
residues mutated to their N domain counterparts. Inhibition constants were determined using 
the Dixon method (44) with fluorogenic peptide substrate Abz-FRK(Dnp)P-OH. 
tACE mutant kA W kAF kAP 
Pocket construct a Ki (JIM) Ki (JIM) Ki (JIM) 
tACE 0.679 0.83 0.05 
S2' T282S(260) 0.920 
S2' E376D(354) 2.33 2.4 
S2' V379S(357) 0.064 0.81 
S2' V380T(358) 2.65 1.9 
S2' V379SN380T 0.870 
S2' D453E(431) 0.618 
S1 S516N(494) 0.497 0.012 
S1 V518T(496) 9.74 18.1 1.3 
S2 F391 Y(369) 4.75 3.9 0.43 
S2 E403R(381) 0.24 
N-dom 854.2 >500 1.5 
• tACE residue and number, followed by the corresponding N domain residue to which it was mutated, with 
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